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Chapter 1: Introduction 
 
1.Glia: The Other Half of the Brain 
 
The recent book, “Driving Mr. Albert” tells the true story of pathologist 
Thomas Harvey, who performed the autopsy of Albert Einstein in 1955. After finishing, 
Harvey irreverently took Einstein's brain home where he kept it preserved in a plastic 
container for the next 40 years. From time to time Harvey doled out small brain slices to 
scientists and pseudoscientists around the world who probed the tissue for clues to 
Einstein's genius. But when Harvey reached his 80’s, he placed what was left of the 
brain in the trunk of his Buick Skylark and embarked on a road trip across the country 
to return it to Einstein's granddaughter (Paterniti M, 2001). 
One of the respected scientists who examined sections of the prized brain was 
Marian C. Diamond, of the University of California at Berkeley. She could 
unfortunately find nothing unusual about the number or size of the neurons in her 
samples. Although on closer examination of the association cortex which is responsible 
for higher-level cognition, she discovered a surprisingly large number of non-neuronal 
cells known as glia at a much greater concentration than that found in the average brain. 
An odd curiosity? Perhaps not. A growing body of evidence suggests that glial cells play 
a far more important role than historically presumed. For decades, physiologists focused 
on neurons as the brain's prime communicators. Glia were thought to serve only a 
maintenance role: bringing nutrients from blood vessels to neurons, maintaining a 
healthy balance of ions in the brain, and warding off pathogens that evaded the immune 
system. Supported by glia, neurons were free to communicate across tiny contact points 
called synapses and to establish a web of connections that allow us to think, remember 
and jump for joy. 
This long-held model of brain function could change dramatically if new 
findings regarding glia prove to be correct. Recent advances in microscopy have shown 
that neurons and glia engage in a two-way dialogue from embryonic development 
through to old age. Glia influence the formation of synapses and help to determine 
which neural connections get stronger or weaker over time; such changes are essential 
to learning and to storing long-term memories. Most recent findings show that glia can 
also communicate amongst themselves, in a separate but parallel network to the neural 
network, influencing how well the brain performs. Neuroscientists are cautious about 
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assigning new prominence to glia too quickly, yet they are excited by the prospect that 
more than half the brain has gone largely unexplored and may contain a trove of 
information about how the mind works. 
Ben Barres’s lab has shown that brains from patients with various neurological 
diseases or injuries show altered glial cell phenotypes (Barres BA et al., 2008). There 
are many questions unanswered regarding the role of glia in the central nervous system 
(CNS): what is the normal function of glial cells, and what is their role in disease? 
Might glial cells be important drug targets? If so, this has the opportuinity to open a new 
avenue of drug therapies for patients suffering from brain injuries and neurological 
disease. 
 
1.1.Glia in health and disease 
 
 
 
Figure 1. Astrocytes can be identified in culture because, unlike other mature glia, they 
express glial fibrillary acidic protein (GFAP). 
 
Glial cells, sometimes referred to as neuroglia or simply glia, are non-neuronal 
cells that maintain homeostasis, form myelin, and provide support and protection for 
neurons in the both the CNS and parts of the nervous system such as in the autonomic 
nervous system (ANS) (Jessen KR and Mirsky R, 1980). In the human brain, there is 
roughly one glia for every neuron with a ratio of about two neurons for every glia cell in 
the cerebral gray matter (Azevedo FA et al., 2009). 
As the Greek name implies, glia are commonly thought of as the “glue” in the 
nervous system; however this is not fully accurate. Currently there are four known 
functions of glia cells. The first is to surround neurons and provide support. Secondly, 
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they supply a steady stream of nutrients and oxygen to the neurons in order for the cells 
to maintain proper homeostasis. Thirdly, to eliminate cross-talk it is important for glia to 
insulate one neuron from another. The fourth and final known function of glial cells is to 
destroy pathogens and remove dead neurons. For over a century, it was believed that 
they did not play any role in neurotransmission. That idea is now discredited; they do 
modulate neurotransmission, although the mechanisms are not yet well understood 
(Gourine AV et al., 2010, Wolosker H et al., 2008). 
 
1.1.1.Microglia 
Microglia are specialized macrophages capable of phagocytosis, protecting 
neurons of the CNS from foreign pathogens. They are derived from hematopoietic 
precursors rather than ectodermal tissue and are commonly categorized as glia because 
of their supportive role for neurons. 
They comprise approximately 15% of the total cells in the CNS and are found 
in all regions of the brain and spinal cord. Microglia cells are small relative to 
macroglial cells, with changing shapes and oblong nuclei. Notably, they are mobile and 
can undergo division following brain injury. In a healthy CNS, microglia processes 
constantly monitor all aspects of their environment including neurons, macroglia and 
blood vessels. 
 
1.1.2.Macroglia 
The most abundant type of macroglial cell, astrocytes (also called astroglia) 
have numerous projections that anchor neurons to their blood supply. They regulate the 
external chemical environment of neurons by removing excess ions, notably potassium, 
and recycling neurotransmitters released during synaptic transmission. The current 
theory suggests that astrocytes may be the predominant "building blocks" of the blood-
brain barrier. Astrocytes may regulate vasoconstriction and vasodilation by producing 
substances such as arachidonic acid, whose metabolites are vasoactive. 
Astrocytes signal to each other through calcium. The gap junctions (also 
known as electrical synapses) between astrocytes allow the messenger molecule inositol 
triphosphate (IP3) to diffuse from one astrocyte to another. IP3 activates calcium 
channels on cellular organelles, releasing calcium into the cytoplasm. This calcium can 
then stimulate the production of more IP3. The net effect is a calcium wave that 
propagates from cell to cell. Extracellular release of Adenosine-5'-triphosphate (ATP), 
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and consequent activation of purinergic receptors on other astrocytes, may also mediate 
calcium waves in some cases. 
In general, there are two types of astrocytes; protoplasmic and fibrous. Both are 
similar in function but distinct in morphology and distribution. Protoplasmic astrocytes 
have short, thick, highly branched processes and are typically found in gray matter. 
Fibrous astrocytes have long, thin, less branched processes and are more commonly 
found in white matter. 
Oligodendrocytes are cells that wrap around axons in the CNS with their cell 
membrane forming a specialized structure referred to as myelin. This produces a myelin 
sheath which provides insulation to the axon and allows electrical signals to propagate 
more efficiently (Baumann N and Pham-Dinh D, 2001). 
Ependymal cells, also named ependymocytes, line the cavities of the CNS and 
compose the walls of the ventricles. These cells create and secrete cerebrospinal fluid 
(CSF) which is then circulated with the help of their beating cilia. They also make up 
the Blood-CSF barrier and are thought to act as neural stem cells (Johansson CB et al., 
1996). 
Radial glia cells arise from neuroepithelial cells after the onset of 
neurogenesis. Their ability to differeniate is more restricted than neuroepithelial cells. In 
the developing nervous system, radial glia function both as neuronal progenitors and as 
a scaffold upon which newborn neurons migrate. In the mature brain, the cerebellum 
and retina retain characteristic radial glial cells. In the cerebellum, these are Bergmann 
glia, which regulate synaptic plasticity. In the retina, the radial Müller cell is the 
principal glial cell, and participates in a bidirectional communication with neurons 
(Campbell K and Götz M, 2002). 
Similar in function to oligodendrocytes, Schwann cells provide myelination to 
axons in the peripheral nervous system (PNS). They also have phagocytotic activity and 
clear cellular debris that allows for regrowth of PNS neurons (Jessen KR and Mirsky R, 
2005). 
Satellite glial cells are small cells that surround neurons in sensory, 
sympathetic and parasympathetic ganglia (Hanani M, 2008). These cells help regulate 
the external chemical environment. Like astrocytes, they are interconnected by gap 
junctions and respond to ATP by elevating intracellular concentration of calcium ions. 
They are highly sensitive to injury and inflammation, and appear to contribute to 
pathological states, such as chronic pain (Ohara PT et al., 2008). 
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Enteric glial cells are found in the intrinsic ganglia of the digestive system. 
They are thought to have many roles in the enteric system, some related to homeostasis 
and muscular digestive processes (Barsotti G et al., 2007) 
 
 
1.2. Glia roles in brain diseases: astroglial cells 
 
Over the past 25 years it has become clear that astrocytes are responsible for a 
wide variety of complex and essential functions in the healthy CNS, including primary 
roles in synaptic transmission and information processing by neural circuit functions. A 
growing body of evidence suggests that the loss of normal function or gain of abnormal 
effects in astrocytes contributes to disease progression. There are now numerous 
examples of how astrocytes contribute to both clinical and pathological mechanisms in 
neurological diseases (Barres BA 2008, De Keyser J et al., 2008, Seifert G et al., 2006, 
Sofroniev MV, 2000). 
Because astrocytes constitute nearly half of the cells in the human brain, there 
is no CNS disease that does not substantially involve astrocytes. Even though astrocyte 
swelling is a dramatic and very harmful component of any acute neurological injury 
including stroke and brain trauma, we still do not understand well why astrocytes are 
more likely to swell than neurons and how this swelling can be lessened. Neurological 
diseases, including dysmyelinating diseases and epilepsy can result from mutations of 
astrocyte genes. Reactive gliosis (astrocytosis) also accompanies every neurological 
disease. Although reactive astrocytosis clearly is beneficial in that it can encapsulate 
infections and help seal a damaged blood-brain barrier, there are many ways in which it 
has been found to be harmful. Glial scarring contributes substantially to the glial cues 
that inhibit severed CNS axons from regenerating (Silver and Miller, 2004). Reactive 
astrocytes upregulate synapse-inducing genes such as thrombospondins, which have the 
potential to help repair the brain (Liauw et al., 2008) but may also induce unwanted 
synapses that can cause epilepsy or neuropathic pain (Boroujerdi et al., 2008). In 
addition, recent studies have found that diseased astrocytes can release a profoundly 
neurotoxic signal. For instance, mutant astrocytes carrying the SOD1 (G93A) allele 
release a toxic signal that rapidly kills wild-type motor neurons (Di Giorgio et al., 2007; 
Nagai et al., 2007; Lobsiger and Cleveland, 2007). 
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The importance of future CNS disease therapies that not only address 
dysfunctional neurons but also glial-cell-controlled inflammatory processes is crucial. 
The involvement of glial cells has been clearly shown in CNS disorders 
including multiple sclerosis (MS), Alzheimer’s disease (AD) (Lue LF et al., 2001), 
stroke (Wang X, 2005), Parkinson’s disease (Hald A, 2005) (PD), Amyothropic lateral 
sclerosis (ALS) (Di Giorgio FP et al., 2008), gliomas, and inflammation (Sofroniew MV 
and Vinters HV, 2010). Development of potential drug targets and therapies would be 
beneficial in treating CNS diseases such as these, particularly those targeted at 
astrocytes which play a central role in these diseases. 
 
 
1.2.1. Neuroinflammation and neurodegenerative diseases. 
 
1.2.1.1. Neuroinflammation 
Features of inflammation in many CNS diseases such for example as AD, have 
been studied over many years, and this topic has been reviewed extensively (Schwab C 
et al., 2008, Rozemuller AJ et al., 2005). There are differences in the cellular 
components and the ways in which inflammation is mediated in the brain (neuro-
inflammation) compared with the periphery. A complex network of cells, signaling 
molecules and molecular mediators of inflammatory responses interact within the brain. 
Astrocytes undergo activation in the areas involved in the disease progress and may 
release a variety of signaling molecules. 
A host of secreted molecules enable communication between astrocytes, 
microglia and neurons. Many of these have been implicated as inflammatory mediators 
in AD and other CNS diseases. Examples include: s100B and α1-anti-chymotrypsin (α1-
ACT), which are produced by astrocytes; cytokines such as TNF-α, IL-1β and IL-6; and 
chemokines such as macrophage colonystimulating factor and macrophage 
inflammatory proteins, which can promote proliferation and trophic support of specific 
types of inflammatory cells. Astrocytes, microglia and neurons are all able to produce 
complement proteins, which may act as direct mediators of inflammation and have been 
detected in neuropathologic studies of various CNS diseases. Together they can produce 
an environmental niche that may be stressful or damaging to surrounding cells.  
7 
In various CNS diseases, it has recently been proposed as an imaging target the 
mitochondrial protein called Traslocator Protein (TSPO) (Chen MK and Guilarte RT, 
2008). TSPO basal expression is up-regulated in a number of human pathologies, 
including a variety of tumors and neuropathologies, such as gliomas and 
neurodegenerative diseases (Huntington’s and Alzheimer’s diseases), as well as various 
forms of brain injury and inflammation (Papadopulus V and Lecanu L, 2009, Chen MK 
and Guilarte RT, 2008). 
In this view, the evaluation of TSPO expression and distribution may represent 
a promising diagnostic marker in pathological conditions, prompting the development 
of new synthetic molecular probes specific for this protein receptor (Doorduin J et al., 
2008). These compounds are generally derivatives of selected ligands that may be 
chemically modified in such a way to retain high receptor affinity and selectivity while 
permitting the visualization of the receptor protein.  
Over the last decade, identification of biomarkers that can reliably detect the 
early stages of CNS diseases has been important in both the design of clinical trials and 
in the accurate identification of research patient populations. Markers that change with 
disease progression may be useful in assessing rates of disease progression and the 
efficacy of potential therapeutics on the pathology. 
Biomarkers used to assess disease severity should be measurable, reproducible, 
and demonstrate changes with disease progression in longitudinal studies. The use of 
such markers in the trials of disease modifying therapies will help to identify the 
appropriate dosage, measure drug efficacy in proof-of-concept trials, and to improve 
safety assessments. 
In recent years, research into biomarker discovery has successfully utilized 
genomics, proteomics, and metabolomics for the identification of several promising 
markers. Targets have been identified in blood, CSF and cells of individuals affected by 
different CNS diseases. These include proteins involved in inflammation, oxidative 
stress, apolipoproteins, and markers of neurodegeneration (Maes et al., 2007). 
While promising, most of these markers have not yet been validated in more 
than one study and their ultimate usefulness awaits further studies. 
Some of these biomarkers can be easily detected in blood or CSF samples, 
while those which are located in the membrane, the cytoplasm, or the nucleus of the 
target cells, require a different kind of detection. Indeed, visualization of these markers 
usually requires specific detection techniques such as antibody staining, in situ 
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hybridization, or autoradiography, unless fluorochromes are used that are detectable 
without further manipulation of the labeled cells. 
An ideal marker should label cells efficiently and stably allowing for the 
specific and sensitive detection of single cells. Most markers only partially fulfill these 
criteria and, therefore, the choice of a certain marker depends on the experimental setup, 
the grade of tissue manipulation needed for marker detection, and the stability of the 
marker in the experimental conditions. 
The use of fluorochromes as probes for the study of proteins has been recently 
considered a valid alternative to traditional methods of study and research in biology. 
They provide a wide range of information on the receptors to which they are related, 
their location and on the interaction of these receptors in viable cells. In addition, 
fluorescent ligands may represent a useful alternative compared to radiolabeled ligands. 
Indeed, fluorescent ligands have higher sensitivity and security and are more cost 
effective compared to radiolabeled ligands. 
Recent studies employing fluorescent compounds capable of specifically 
binding cell surface receptors whose density is altered in CNS diseases, have 
highlighted the possibility of using these new ligands as probes for diagnostic imaging 
(Daly CJ et al., 2003, Taliani S et al., 2007). The success of these observations depends 
on the ability of the probe to bind the receptor specifically at low concentrations during 
both positron emission tomography (PET) and single photon emission tomography 
(SPECT). The same probes, when used in techniques such as computed tomography 
(CT) and magnetic resonance imaging tomography (MRT), however, require higher 
concentrations. Generally, to be used as a probe, the ligands must have a high affinity 
for the receptor. In addition it should be possible to remove the ligand in excess from 
the tissue under examination simply washing the sample. This may represent a limit for 
the studies because experiments conducted on tissues have shown that the techniques 
used for washing cause often an alteration of the chemical equilibrium with consequent 
detachment of the fluorescent ligand from the receptor. Finally, the probe must display a 
good resolution image even at low concentrations. 
Another versatile tool for the study of receptors are irreversible ligands. 
(Newman AH, 1991). These agents have been invaluable in the characterization, 
isolation and purification of a number of receptor systems, including TSPO. This has 
allowed for a greater understanding of their physiological and pharmacological 
properties, which aid in designing better therapeutic compounds. The strategy is to 
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introduce on a high affinity ligand a chemical moiety that permits the covalent binding 
to the receptor protein.  
In chapter 2 the biological characterization of two novel irreversible ligands as 
well as an irreversible fluorescent ligand to TSPO is described in detail. 
 
1.2.1.2. Neurodegenerative diseases: Amyotrophic lateral 
sclerosis  
ALS is characterized by premature death of upper and lower motor neurons 
starting in adulthood. The pathology of ALS is characterized by abnormal accumulation 
of insoluble and misfolded proteins in degenerating motor neurons. Neuronal death 
results in progressive paralysis, which typically is fatal 2–5 years after the onset due to 
respiratory failure. Ten percent of ALS cases are inherited, while the rest are considered 
sporadic and the cause has not been discovered yet. Twenty percent of inherited ALS 
cases are caused by mutations in the gene encoding for superoxide dismutase 1 (SOD1) 
(Rosen DR et al., 1993, Pasinelli P and Brown RH, 2006). SOD1, a ubiquitously 
expressed enzyme, catalytically converts reactive superoxide to oxygen and hydrogen 
peroxide. It is now recognized that all mutations of the SOD1 gene (both enzymatically 
active and inactive mutants) uniformly cause toxicity in cells not by loss but rather by 
gain of function where accumulation of protein in neurons and glia causes toxicity. 
However, the exact mechanisms and nature of toxicity is still unknown (Bruijn LI et al., 
2004, Turner BJ and Talbot K, 2008). Currently, numerous mechanisms of toxicity have 
been proposed that could mediate pathology in mutant SOD1-mediated ALS. The most 
important mechanisms are thought to be excitotoxicity from glutamate, failure of 
protein degradation machinery, endoplasmic reticulum stress, damage to mitochondria, 
superoxide generation through neuroinflammation, axonal transport disruption, etc. 
(Rothstein JD et al., 1995, Yang Y et al., 2009, Kikuchi H et al., 2006, Liu J et al., 2004, 
Harraz MM, 2008, Williamson TL and Cleveland DW, 1999, Zhong Z et al 2008). 
There is good evidence for all of these mechanisms to be at play, and most 
likely it is a combination of different events that contribute to the overall development 
of ALS pathology. 
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Figure 2. Molecular mechanisms of motorn neuron injury in ALS. ALS is a complex disease 
involving activation of several cellular pathways in motor neurons, and in dysregulated interaction with 
neighboring glial cells. Microglia activate an inflammatory cascade via secretion of MCP-1 and other 
cytochines. Astrocytes contribute to motor neuron injury through various mechanisms, including release 
of inflammatory ediators such as NO and PGE2; reduced expression and activity of the glutamate 
reuptake transporter EAAT2; reduced lactate release; and activation of pro-NGF-p75 receptor signaling. 
Motor neurons might also undergo transcriptional dysregulation and abnormal RNA processing which, 
together with overproduction of ROS, contribute to aberrant protein folding. Aberrant proteins can form 
aggregates, leading to proteasome impairment and ER stress, and ultimately activating autophagy and 
apopthotic pathways. Mitochondrial impairment and dysregulation of calcium handling are two major 
components of motor neuron injury that also lead to activation of the apoptotic cascade that is observed in 
ALS. Motor neurons can produce and secrete complement subunits that are important signals of cellular 
stress to neighboring cells. Abbreviations: ALS, Amyotrophic lateral sclerosis; EAAT2, excitatory amino 
acid transporter 2, ER, endoplasmic reticulum; IL, interleukin; MCP-1, monocyte chemoattractant 
protein; NGF, nerve growth factor; NO, nitric oxide; PGE2, prostaglandin E2; ROS, reactive oxygen 
species. 
[Modified from Ferraiuolo L et al., 2011] 
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The discovery of SOD1 mutations led to the development of animal models 
that recapitulate ALS-like disease. Overproduction of mutated human SOD1 protein in 
these mouse models leads to a progressive neurodegenerative disease that closely 
resembles human pathology with a selective motor neuron death and gliosis 
accompanied by accumulation of misfolded proteins (Gurney ME et al.,1994.). 
Originally, the selective death of motor neurons was believed to be caused by a 
cell autonomous mechanism. However, through genetic and chimeric mice studies there 
is indication that it may actually be non-cell autonomous mechanisms. These studies 
showed that when expression of SOD1 mutations was restricted to either motor neurons 
or astrocytes, but not in both simultaneously, it did not lead to the development of ALS 
(Lino MM et al., 2002, Pramatarova A et al., 2001, Gong YH et al., 2000.). Other labs 
have succeeded in producing very late onset disease in mice when mutant is expressed 
in only neurons (Jaarsma D et al., 2008). However, the severity and speed at which the 
disease progressed in the mice was much more modest when compared to mice 
expressing the same mutant gene ubiquitously. 
Next wild-type neurons were analysed in chimeric mice containing both 
wildtype and mutant SOD1-expressing cells. They showed that neurons surrounded by 
glial cells bearing SOD1 mutation acquired an ALS phenotype (Clement AM et al., 
2003). When they excised the mutant floxed SOD1 gene in either astrocytes or 
microglia through the use of a Cre recombinase, they saw a slowing in the disease 
progression and an extension in life expectancy (Yamanaka K et al., 2008, Boill´ee S et 
al., 2006, Wang L et al., 2009, Wang L et al., 2011). Immunohistological studies also 
showed glial cell involvement in ALS pathology where astrogliosis and microgliosis are 
considerable hallmarks of the disease (Hall ED et al., 1998, Alexianu ME et al., 2001). 
Among the non-neuronal cell types, a role of glial cells, and in particular of astrocytes, 
in ALS has been most intensively investigated. 
Evidence is available suggesting two quite different potential roles for 
astrocytes in ALS or motor neuron disease, through either the loss of a neuroprotective 
function or the gain of a neurotoxic effect. Sporadic ALS is characterized by selective 
loss or dysfunction of astrocyte glutamate transporters in spinal cord and cerebral 
cortical areas that exhibit loss of lower and upper motor neurons, suggesting that 
increased glutamate excitotoxicity may contribute to motor neuron death and raising the 
possibility of different types of potential interventions (Fray AE et al., 1998, Maragakis 
NJ and Rothstein JD, 2006, Rattray M and Bendotti C, 2006, Rothstein JD et al., 1992). 
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A high-throughput screen of small molecules has identified that certain β-lactam 
antibiotics can stimulate the expression of glutamate transporters in astrocytes and 
thereby enhance glutamate uptake sufficiently enough to reduce excitotoxicity, and 
provide neuroprotection in animal models of stroke and ALS (Rothstein JD et al., 2005). 
The β-lactam antibiotic, Ceftriaxone, began stage 3 clinical trials in May 2009 
to determine efficacy in reducing excitotoxicity and neurodegeneration in ALS. Focal 
grafts of healthy astrocytes are reported to be neuroprotective in an animal model of 
ALS, suggesting that transplantation of astrocytes may be a potential therapeutic 
strategy (Lepore AC et al., 2008). 
A second role that can be attributed to deleterious astrocytic behavior in ALS is 
an insufficient release of neurotrophic factors that are important in maintaining neuronal 
health. Glial-derived neurotrophic factor, brain derived neurotrophic factor, ciliary 
neurotrophic factor, and vascular endothelial growth factor are all released by astrocytes 
and can rescue motor neurons (Ekestern E, 2004, Dewil M et al., 2007). A loss of 
neurotrophins if not directly, then indirectly, might be a cause of neuronal death. In 
addition to neurotrophins, astrocytes may release hazardous factors. In vitro studies 
confirm that factors released by SOD1 astrocytes in culture media can induce apoptosis 
in motor neuron cultures. One of the identified toxic factors is neurotrophic growth 
factor (NGF) (Pehar M et al., 2004). Similarly, wild-type embryonic stem (ES) cell-
derived motor neurons co-cultured with mutant SOD1-expressing glial fibrillary acidic 
protein (GFAP) positive astrocytes are induced to degenerate and die indicating non-cell 
autonomous degeneration mechanism (Nagai M et al., 2007, Di Giorgio FP et al., 2008, 
Di Giorgio FP et al., 2007, Marchetto MCN et al., 2008). 
The role of astrocytes in ALS pathology has been widely recognized and 
appreciated. Astrocytes have become an interesting therapeutic target, and many new 
studies are looking at various forms of intervention.  
The transcription nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the 
expression of genes containing antioxidant response element (ARE), which are 
preferentially activated in astrocytes. An attempt to activate Nrf2-ARE in astrocytes has 
been successful in protecting neighboring neurons in vitro, and extends the survival in 
ALS mice (Vargas MR et al., 2008). Increased level of glutathione [ɣ-l-glutamyl-l-
cysteinylglycine (GSH)] seems to be a major component of the protection conferred by 
Nrf2 activation. Glutathione is synthesized by the consecutive action of two enzymes, 
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glutamate-cysteine ligase (GCL) and glutathione synthetase. Nrf2 regulates both 
enzymes and GCL is the rate-limiting enzyme for glutathione synthesis. 
Increased production and secretion of glutathione by astrocytes is known to 
improve the antioxidant status of co-cultured neurons and protect them from oxidative 
insults (Dringen et al., 2000). 
In this view, the identification of activators of Nrf2-ARE pathway in astrocytes 
may represent a promising strategy to extend the survival of patients suffering from 
ALS. 
Chapter 3 will describe the experiments I performed during the period I spent 
at the Sheffield Institute for Translational Neuroscience, SITraN, (Sheffield University, 
UK). There I screened two libraries of small molecules on different cell lines (as C6 rat 
astrocyte cell line) in order to identify activators of Nrf2-mediated transcription. 
 
 
1.2.2.Glioblastoma multiforme 
 
Glioblastoma multiforme (GBM, WHO grade IV) is the most malignant 
common cancer of the central nervous system and is particularly resistant to 
chemotherapy currently in use. The GBM represents approximately 60% of all primary 
malignant brain tumors, and although the techniques in neurosurgery, radiotherapy and 
the introduction of new cancer agents have improved, the overall survival is still low, 
particularly in patients with recurrent or refractory GBM.  
Histologically it is characterized by the proliferation of vascular endothelial 
(neoangiogenesis) and large areas of necrosis with consequent alteration of the blood-
brain barrier. The GBM mainly affects adults and occurs more often in the subcortical 
white matter of the cerebral hemispheres. The sites most commonly affected are the 
temporal lobe (31%), the parietal lobe (24%), the front (23%) and occipital lobes (16%) 
with the typical combination being fronto-temporal (Kleihues P et al., 2007). Less 
frequently they are localized to the cerebellum, brainstem and spinal cord. Except in 
very rare cases, GBM’s do not expand beyond the structures of the CNS. 
Glioblastoma can develop from a diffuse astrocytoma or an anaplastic 
astrocytoma (secondary glioblastoma) but more frequently occurs de novo, without any 
evidence of previous cancer (primary glioblastoma) (Figure 3).  
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Figure 3. 
 
The GBM cells of origin, whether potentially astrocytes, glial precursors, or 
stem cells, are the subject of intense investigation (Furnari FB et al., 2007). Consistent 
with the cancer stem cell hypothesis, there is considerable evidence that only minor 
populations of cells in primary gliomas are capable of forming a tumor, (Furnari FB et 
al., 2007, Singh SK et al., 2004). The GBM contains small numbers of cells that exhibit 
stem cell-like properties, called brain tumor stem-like cells (BTSC) (Charles NA et al., 
2011), in that they self-renew, are multipotent and form neurospheres in vitro and 
constitutively produce the different types of cells found within the parent tumors 
(Nakano I and Kornblum HI, 2009). Growth properties of glioma-derived neurospheres 
in vitro were found to be significant predictors of tumor progression in vivo and of 
clinical outcome (Laks DR et al., 2009). Nevertheless, the origins of gliomas are not yet 
understood and could be heterogeneous. 
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Figure 4. The glioblastoma microenvironment is composed of several stromal cell types, 
each of which are believed to make distinct contributions to tumor progression and invasion. These cells 
include but are not limited to astrocytes, macrophages, pericytes, fibroblasts, and endothelial cells. 
 
BTSCs are refractory to conventional therapy that includes radiation therapy 
and chemotherapy with alkylating agents of DNA (Salmaggi A et al., 2006), also the 
blood-brain barrier provides extra resistance to chemotherapy because it makes difficult 
the distribution of drugs from the blood to the brain tissue. 
Alkylating agents are the most widely used chemotherapeutic agents to treat 
GBM. Among the chemotherapeutic compounds used is temozolomide (TMZ), a 
cytotoxic alkylating agent, has shown activity in recurrent glioblastomas (Brada M et 
al., 1999; Conrad CA et al., 1995; Hirose Y et al., 2001; Levin VA et al., 2001). 
It has delayed tumour progression and prolonged patient survival; however, 
many patients develop resistance to this drug, have tumour recurrence, and typically 
survive only 12-15 months after diagnosis.  
Therefore, new approaches are essential for the treatment of these patients, 
especially because the occurrence of gliomas is increasing (Hess KR et al., 2004, 
Johannesen TB et al., 2004). 
In chapters 4 and 5 the biological characterization of novel promising 
molecules acting on different interesting targets for glioma therapy is reported. 
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Chapter 2: Neuroinflammation 
 
Translocator Protein (TSPO) 
 
Previously named the peripheral benzodiazepine receptor (PBR), the 
translocator protein is an 18 kDa protein located primarily in the outer membrane of 
mitochondria. The earliest term, PBR, was widely accepted in the scientific community 
even though multiple other names have been used to identify this protein, including 
mitochondrial benzodiazepine receptor, mitochondrial diazepam-binding inhibitor 
receptor complex, isoquinoline-binding protein, pk18 and ω3 (Papadopoulos V et al., 
2006). Although each name identified specific properties, none of them completely 
reflects the nature and function of TSPO. For this reason, the scientific community has 
progressively supported renaming of the protein, from PBR to TSPO, with the aim of 
accurately representing the subcellular roles and putative tissue-specific functions. 
TSPO was first identified as a benzodiazepine-binding site outside the central 
nervous system (Braestrup C et al., 1977). 
In addition to benzodiazepine derivatives (i.e., Ro5-4864), TSPO binds high-
affinity endogenous ligands, such as protoporphyrin IX, diazepam-binding inhibitor, 
triakontatetraneuropeptide, phospholipase A2 and cholesterol (Ferrero P et al., 1986, 
Slobodyansky E et al., 1989, Snyder MJ et al., 1998, Lacapère JJ et al., 2003). It is also 
able to bind synthetic ligands, including isoquinolines (i.e., PK11195), imidazopyridines 
(i.e., Alpidem), indole derivatives (i.e., FGIN-1-27 and SSR180575), 
pyrrolobenzoxazepines and phenoxyphenyl acetamide derivatives (i.e., DAA1106). 
TSPO contains 169 amino acids that are arranged in five transmembrane segments, each 
of which is composed of approximately 21 amino acids in an α-helical structure 
(Joseph-Liauzun E et al., 1998). Potential binding sites for ligands have been described 
in the literature. For instance, the first cytoplasmic loop (L1) seems to be essential for 
the binding of PK11195, Ro5-4864 and benzodiazepines. The TSPO-binding site for 
carboxamide derivatives involves two loops (L1 and L3). Finally, the C-terminal region, 
located on the cytoplasmic side of the membrane, has been shown to be part of the 
binding site for cholesterol (Joseph-Liauzun E et al., 1998). 
TSPO has been found in the entire animal kingdom, including insects, 
molluscs, amphibians, aves and mammals. Apart from its abundance in peripheral 
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tissues (Braestrup C et al., 1977, Verma A et al., 1989), TSPO is also present in glial 
cells (Syapin PJ et al., 1979, Schoemaker H, et al., 1983). 
At the subcellular level, TSPO is reported to be located primarily in 
mitochondria, at the contact sites between the outer (OMM) and inner (IMM) 
mitochondrial membranes (Anholt RR et al., 1986, Antkiewicz-Michaluk L et al., 1988, 
Culty M et al, 1999). 
The topography and organization of TSPO have been investigated by 
transmission electron and atomic force microscopy performed on mitochondrial 
preparations; these images showed that TSPO forms clusters containing four to six 
molecules. Notably, after hormonal treatment, the formation of 15–25 gold particle 
clusters, larger than the previous clusters, has been described (Papadopoulos V, et al, 
1999). Furthermore, UV photoirradiation of recombinant TSPO stimulates polymer 
formation, probably due to the generation of reactive oxygen species, and spectroscopic 
analysis revealed the formation of dityrosines as covalent cross-linkers between TSPO 
monomers (Delavoie F et al., 2003, Papadopoulos V et al., 1999). 
Many cellular functions are directly or indirectly associated with TSPO, 
including regulation of cholesterol transport, synthesis of steroid hormones, porphyrin 
transport, heme synthesis, anion transport, regulation of mitochondrial functions, 
immunomodulation, cell proliferation and apoptosis. In particular, TSPO is largely 
involved in the complicated apoptotic mechanism, forming a mitochondrial protein 
complex in association with the voltage-dependent anion channel (VDAC) and the 
adenine nucleotide transporter (ANT). These three proteins are the core components of 
the mitochondrial permeability transition pore (MPTP) (Maaser K et al., 2001) (see 
Figure 1). 
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Figure 1. The mithocondrial protein complex (Taken from Papadopoulos et al., 2006). 
 
As previously reported, clinical investigations have revealed that PBR basal 
expression is up-regulated in a number of human pathologies, including a variety of 
tumors. Furthermore, significantly enhanced PBR expression has been observed in 
neurodegenerative diseases (Huntington’s and Alzheimer diseases and Multiple 
sclerosis), as well as in various forms of brain injury and inflammation (Chen MK and 
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Guilarte RT, 2008). All these findings have stimulated the development of new ligands 
targeting TSPO as powerful tools to image and measure the expression level of this 
protein in both humans and animals (Fookes C J et al., 2008, Briard E et al, 2008, Dollè 
F et al, 2009, Taliani S et al., 2010). 
Fluorescent ligands represent a safer faster and less-expensive alternative to 
radioligands in probing the ligand-receptor complex. Fluorescent agents with high 
specificity and attractive spettroscopic properties are therefore needed in the field of 
biomedical research. 
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Experimental section 
 
 
Novel irreversible fluorescent probes targeting the 18kDa 
translocator protein: biological characterization 
 
In this field, Taliani et al. have recently developed novel highly potent and 
selective fluorescent probes targeting TSPO with the general formula II, designed as 
derivatives of the highly potent N,N-dialkyl-2-phenylindol-3-ylglyoxylamide ligands I, 
(Primofiore G et al., 2004, Da Settimo F et al., 2008) featuring the fluorescent moiety 
linked to the N-alkyl chain (see Figure 2) (Taliani S et al., 2007). For these compounds, 
the researchers selected the well-known 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) group 
as the fluorophore, because its small size does not generally affect affinity of the parent 
ligand (Taliani S et al., 2007). 
Tissue experimental procedures using a labelled ligand often cause the 
alteration of the chemical equilibrium and the subsequent loss of the bound fluorescent 
ligand. To overcome this problem, some high affinity ligands which bind covalently to 
the receptor protein have been developed (Taliani S et al., 2007). 
In this chapter the biological characterization of a series of 2-phenylindol-3-
ylglyoxylamides, and the test of their validity as new TSPO probes is reported. All of 
these compounds are characterized by the presence of a chemoreactive isothiocyanate 
group, able to bind the receptor protein irreversibly and covalently (compounds 7-8, 
Figure 2). Moreover, compound 18 (Figure 2) featuring the NBD-fluorescent moiety 
was synthesized to develop an irreversible fluorescent probe. The presence of these two 
devices (a chemoreactive group and a fluorescent chromophore) on a single molecule 
may offer a multiplicity of advantages, both in protein purification/characterization, and 
in protein cell visualization/density determination. 
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Figure 2. Structures of Known (I and II) and Novel (7, 8, and 18) TSPO Ligands 
 
 
Materials and methods 
 
Materials  
[3H]Ro 5-4864 (s.a. 70.0 Ci/mmol) was purchased from Perkin-Elmer Life 
Sciences. Ro 5-4864 powder was obtained from Sigma-Aldrich. 
Compounds 7, 8 and 18 were synthesized in the laboratory of Professor Da 
Settimo at the University of Pisa.  
 
Cell culture  
The human GBM cell line U87MG was obtained from the National Institute for 
Cancer Research (ICLC) of Genoa. The U87MG cell (1x10
6
) were seeded onto 10 cm 
plates and cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), 
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 1% non-essential 
amino acids, at 37°C in humidified atmosphere composed of 5% CO2 and 95% O2. 
After 24 h the medium was replaced by 2ml of serum-free RPMI 1640 containing 2mM 
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L-glutamine, 100 U/ml penicillin, 100mg/ml streptomycin and 1% of non-essential 
amino acids. 
 
[3H]Ro 5-4864 binding to Rat Kidney Mitochondrial 
Membranes: reversible binding  
The binding studies were carried out essentially as previously described 
(Taliani S et al., 2007, Selleri, S et al., 2005). 
 
Time course of binding of the new ligands to the TSPO 
receptor: irreversible binding 
The binding studies were carried on essentially as previously described 
(Martini C et al., 1987). Briefly, rat kidney membranes were incubated with each 
compound (concentration range: 1 nM - 1 µM) for different times (0, 10, 30, 60, 90 and 
180 min), in binding assay buffer. Incubations were stopped by the addition of 1 ml of 
ice-cold 50 mM Tris/HCl buffer (pH 7.4), and then the samples were centrifuged for 15 
min at 13,000 x g at 4 °C. Pellets were washed twice with cold binding buffer. Then, 
samples were processed for determination of protein content. [3H]Ro 5-4864 binding 
assays were performed in a final volume of 500 µl of binding assay buffer containing 
membranes (65 µg of protein/tube), as mentioned above. 
 
Fluorescent labelling of human glioma cells  
U87MG cells were cultured in 96-well plates (4x10
4
 cells/well) in RPMI 1640 
complete medium. After 24 h, the cells were incubated with different concentrations of 
compound 18 (100 nM, 250 nM and 500 nM) in cell culture medium, for 20 and 90 
minutes, under 5% CO2 at 37 °C. In parallel, some samples were incubated with Ro 5-
4864 10 µM prior to add compound 18. To remove the excess of unbound compound, 
the cells were washed four times with cell medium with cysteine, a molecule able to 
react with the isothiocyanate group. After washing, PBS was added to the cells and the 
fluorescence intensity (Ex:485 nm; Em: 535 nm) from each sample was measured by 
Victor Wallac 2 (Perkin Elmer, Boston, USA). All data are presented as means ± SEM, 
derived from at least three independent experiments done in duplicate. 
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Data Analyses 
 Data were analysed by use of the GraphPad Prism software (GraphPad 
Software, version 4.0; San Diego, CA). Statistical analyses were performed by one-way 
ANOVA (with post hoc Bonferroni test). 
 
 
Results  
 
As a first step, the equilibrium binding parameters (IC50 and Ki values) of the 
test compounds were derived by competition experiments against [3H]Ro 5-4864 in rat 
kidney membranes. Ro 5-4864 was used as the reference standard, showing a Ki value 
of 23 nM. The curves of [3H]Ro 5-4864 displacement by the irreversible ligands 7 and 
8, and by the fluorescent ligand 18 are shown in Figure 3. Binding data for the three 
ligands 7, 8, and 18 are listed in Table 1: all compounds showed affinity values in the 
nanomolar range, comparable to that of the reference standard Ro 5-4864 (Ki from 37.6 
nM to 49.5 nM). 
 
a) 
 
 
 
 
 
 
24 
b) 
 
 
c) 
 
 
 
Figure 3. Displacement of [3H]Ro 5-4864 by compound 7 (a), 8 (b), and 18 (c) in rat kidney 
mitochondria membranes. Bound radioactivity is expressed as a percentage of specific binding in the 
presence of competitor molecule. Points represent the mean values ± SEM of triplicate determinations 
pooled from three independent experiments. 
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Compound IC50 (nM) Ki (nM) 
7 45.6±0.4 37.9±0.4 
8 59.7±0.6 49.5±0.5 
18 42.2±0.4 37.6±0.4 
Ro 5-4864 - 23±3.1 
 
Table 1. Values of IC50 and Ki for compounds 7, 8, and 18 obtained from three independent 
equilibrium binding assays. The IC50 values were converted to an absolute inhibition constant Ki, using 
the Cheng-Prusoff equation (Cheng Y and Prusoff WH, 1973). Data are shown as values ± SEM. 
  
In order to investigate the potential covalent binding of compounds 7, 8, and 18 
to TSPO, the samples derived from competition radiobinding assays were diluted more 
then ten times with fresh buffer at the end of the incubation time: data did not markedly 
change with respect to those obtained in the undiluted samples (data not shown). This 
observation indicates that the TSPO-ligand interaction is irreversible, and it 
immediately disqualifies the application of the Cheng-Prusoff equation (Cheng Y and 
Prusoff WH, 1973) in binding parameter analysis. 
With the aim of evaluating the rate order of the binding reaction, a kinetic 
analysis method was developed, as reported in literature (Liu-Chen LY et al., 1975, 
Taliani S et al., 2007). Results showed that mitochondrial membrane pre-treatment with 
newly synthesized TSPO ligands inhibited the [3H]Ro 5-4864 binding to TSPO. This 
inhibition was time- and ligand concentration-dependent, as showed in Figure 4, where 
B is binding after pre-treatment of membranes with different concentrations of TSPO 
ligands for several times, and B0 is control binding. When the B and B0 ratio was 
plotted on a logarithmic scale versus incubation times, the decrease in the ln B/B0 
values appeared to be linearly related to the pre-incubation time. Therefore, inactivation 
proceeded according to apparent first-order kinetics. 
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a) 
 
b) 
 
c) 
 
 
Figure 4. Time course of compounds 7 (a), 8 (b) and 18 (c) binding to receptor. The semi 
logarithmic representation of the decrease in [
3
H]Ro 5-4864 binding to TSPO by pre-treatment (0, 10, 30, 
60, 90 and 180 min) with various concentrations of compound 18 is shown. Points represent the mean 
values ± SEM of duplicate determinations pooled from three independent experiments. 
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The apparent first-order rate constant (Kobs) was defined by equation 1: 
 
             [eq. 1] 
 
Thus, a mathematical analysis was conducted to calculate the dissociation 
constant (Kd) of the reversible receptor-ligand complex, and the pseudo first-order rate 
constant (K2) for the irreversible interaction between the receptor and the irreversible 
ligand, as previously reported by Liu-Chen and colleagues (Liu-Chen LY et al., 1975). 
The mathematical equation describing the process is shown below (eq. 2):  
 
        [eq. 2] 
 
Kobs is the observed first-order rate constant for irreversible binding, and it is 
derived from the slope of the different straight lines shown in Figure 4. The plotting of 
1/Kobs versus 1/[D] (where D is the ligand concentration) gave a straight line that 
intercepted the ordinate and abscissa axes at 1/K2 and -1/Kd, respectively. The slope of 
the line was the ratio Kd/K2 (Figure 5). K2 and Kd values of each compound are listed 
in Table 2. Interestingly, all the Kd values are in the nanomolar range (Kd from 3.17 to 
8.31 nM), confirming an effective interaction with the receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tK
B
B
obs 
0
ln
  22
111
KDK
K
K
d
obs

28 
a) 
 
b) 
 
c) 
 
 
Figure 5. Calculation of K2 and Kd for ligand 7 (a), 8 (b) and 18 (c). On the basis of data 
obtained by three different experiments carried out in duplicate, the values were calculated in accordance 
with equation 2. Data are shown as mean values ± SEM. 
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Compound K2 (nM) Kd (nM) 
7 0.003±0.001 3.17±0.31 
8 0.015±0.002 5.07 ±0.61 
18 0.012±0.002 8.31±0.89 
 
Table 2. Values of K2 and Kd. for the irreversible binding of compounds 7, 8, and 18 to TSPO. 
Data, obtained from 3 independent kinetic assays, are shown as values ± SEM. 
 
To estimate the ability of compound 18 to permeate cell membranes, a number 
of its physicochemical properties were calculated and reported in Table 3. Values 
obtained were consistent with an adequate distribution of 18 into the cell. 
 
a
 Calculated n-octanol/water partition coefficient. 
b
 Total Solvent Accessible 
Surface Area. 
c 
Polar Surface Area. 
d
 Number of atoms. 
e 
Number of rotatable bonds. 
f
 
Molecular weight. 
 
Table 3. Physicochemical predicted properties of compound 18. 
 
The ability of the probe to specifically and irreversibly label TSPO was 
evaluated in live cells of human glioma, using fluorescence spectroscopy. For this 
purpose, U87MG glioma cells were incubated with different concentrations of 18 (100, 
250 and 500 nM) after pre-treatment with buffer (control) or with 10 µM Ro 5-4864. 
Incubation was performed at 90 min, a time in which the irreversible bound is formed 
(see equations 2 and 3), and at a shorter time (20 min). As expected, at the shortest time 
the detected values of fluorescence intensity were smaller than the mean values obtained 
after 90 min (Figure 6, panel A and B, respectively). Interestingly, at 20 min time 
incubation, Ro 5-4864 was able to displace compound 18 in a similar extent for all the 
concentrations assayed, demonstrating the specificity of ligand 18-TSPO binding. 
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Conversely, in the experiments performed at the longest time, Ro 5-4864 showed to be 
unable to displace 18, demonstrating the irreversibility of the bond. 
 
 
 
Figure 6. Human glioma cell staining with the irreversible fluorescent TSPO ligand 18. The 
cells were incubated with compound 18 for 20 min (A) and 90 min (B), in the absence or presence of 10 
µM Ro 5-4864 (grey bars). Data were obtained from 3 independent assays and are shown as mean values 
of Fluorescence Intensity ± SEM. 
 
 
Conclusion 
 
In conclusion, we biologically characterized novel irreversible TSPO ligands 
featuring the 2-phenylindol-3-ylglyoxylamide scaffold. The binding of these compounds 
to the receptor was investigated in detail, characterizing both order rate and kinetic 
constants. Experimental data showed that all the new derivatives effectively bind the 
receptor by means of an irreversible covalent interaction. Fluorescence spectroscopy 
experiments performed on derivative 18, featuring an NBD fluorophore group, revealed 
its ability to specifically and irreversibly label TSPO in live U87MG glioma cells. All 
these novel irreversible TSPO ligands represent useful tools in the investigation of the 
physiological role of TSPO and in the detection of its expression levels.  
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In particular, the fluorescent probe 18 may be employed as diagnostic marker 
to evaluate the TSPO expression in peripheral cells, post-mortem and biopsy tissues, 
from patients affected by diseases in which the TSPO density is altered. Actually, 
irreversible probes offer the advantage of a lasting detection in visualization techniques 
that generally require multiple washes to remove the non-specific signal, steps in which 
reversible probes may be lost. 
Complementary investigations using irreversible and reversible fluorescent 
TSPO ligands, in in vitro and in vivo studies, respectively, may offer a useful platform 
for the development of new diagnostic approaches in many CNS diseases such as 
neuroinflammation and neurodegeneration.  
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Chapter 3: Neurodegenerative diseases 
 
Nrf2-ARE pathway: implications in Amyotrophic lateral sclerosis 
 
Oxidative damage seems to play a major role in the pathogenesis of chronic motor 
neuron death in ALS based on the following lines of evidence: i) markers of oxidative 
damage of proteins, lipids, and DNA are elevated in brain and spinal cord in both mutant 
superoxide dismutase 1 (SOD1) ALS-mouse models (Gurney ME et al., 1994) and in 
human familial and sporadic ALS (Aguirre N et al., 2005, Beal MF et al. 1997, Ferrante RJ 
et al. 1997, Perluigi M et al., 2005), and ii) a large number of antioxidant compounds have 
been shown to be neuroprotective in ALS mouse models. 
A major transcriptional modulator of the cellular antioxidant response is the 
transcription nuclear factor erythroid 2-related factor 2, NRf2. After activation and 
translocation to the nucleus, NRf2 binds to the ARE, a regulatory enhancer region within 
gene promoters, thus regulating the expression of more than 200 genes involved in the 
cellular antioxidant and anti-inflammatory defense. Among these are the classical phase 2 
detoxification enzymes such as NAD(P)H quinone oxidoreductase and glutathione, 
enzymes that are necessary for glutathione biosynthesis, extracellular superoxide 
dismutase, glutamate-6-phosphatedehydrogenase, heat shock proteins, and ferritin (Figure 
1). Furthermore, pro-inflammatory and anti-inflammatory enzymes such as 
cyclooxygenase 2, inducible nitric oxide synthase, and heme oxygenase-1 are also 
regulated in this manner (van Muiswinkel FL et al. 2005, Shih AY et al., 2005). 
In addition to its role in inducing ARE-dependent gene transcription, Nrf2 also 
has direct cytoprotective effects via the inhibition of Fas-triggered apoptotic pathways 
(Kotlo KU et al., 2003). 
Neuronal and astroglial cells from Nrf2 knockout mice are more vulnerable to 
oxidative stress than wild-type cells in vitro, and overexpression of Nrf2 increases 
resistance against oxidative and excitotoxic stimuli (Shih AY et al., 2005, Kraft AD et al., 
2004, Lee JM et al., 2003). 
The translocation of Nrf2 to the nucleus is inhibited by the actin-bound 
cytoskeletal zinc metalloprotein Kelch-like ECH-associated protein1 (Keap1), which 
interacts with Nrf2 and leads to its sequestration and subsequent degradation by the 
ubiquitin-proteasome system. Decreased Keap- Nrf2 binding (via oxidation of sulfhydryl 
groups or phosphorylation) results in intranuclear shuttling of Nrf2 and subsequent 
33 
transcription of ARE-driven genes (van Muiswinkel FL et al. 2005). Therefore, Keap1 and 
Nrf2 constitute a mechanism by which cells can sense damage caused by free oxygen 
radicals (Itoh K et al., 1999) (see Figure 2). 
Recent evidence has emerged that Nrf2–ARE signaling may be dysregulated in 
mSOD1 models of ALS, and in the CNS of patients with ALS. 
Multiple studies have shown that oxidative stress interacts with, and potentially 
exacerbates, other pathophysiological processes that contribute to motor neuron injury, 
including excitotoxicity, mitochondrial impairment, protein aggregation, ER stress, and 
alterations in signaling from astrocytes and microglia. Thus, effective alleviation of 
oxidative stress could potentially ameliorate multiple facets of the pathobiology of motor 
neuron degeneration. A meta-analysis of therapeutic interventions tested in mSOD1 mice 
up to 2007 concluded that antioxidant therapies were the most effective class of drug at 
improving survival (Benatar M, 2007). Antioxidants have not yet shown benefit in patients 
with ALS, although the reported trials have often been of suboptimal design (Orrell R et 
al., 2007). 
On these bases, is evident the need for molecules able to activate the Nrf2-ARE 
pathway and exert an antioxidant activity in ALS therapy.   
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 Figure. 1. Coordinated upregulation of cytoprotective genes occurs as a result of Nrf2 activation. 
Nrf2-dependent genes identified by microarray are listed in bold italics. These genes function together in the 
production and utilization of glutathione. Genes involved in cellular uptake of glutathione-constituent amino 
acids glycine and glutamate are increased. Additionally, the rate-limiting step of glutathione synthesis is the 
formation of the -glutamyl cysteine moiety by -glutamyl cysteine ligase. Transcription of both subunits of 
this enzyme is induced. Moreover, enzymes responsible for glutathione utilization, reduction, and 
conjugation are all represented in microarray data. Similarly, production and use of the common 
detoxification enzyme cofactor NADPH is stimulated. The pentose phosphate pathway is a common cellular 
mechanism whose two main functions are the production of reduction equivalents in the form of NADPH and 
the production of ribulose-5-phosphate for nucleotide and nucleic acid synthesis. In the case of Nrf2 
activation, the pathway is focused on NADPH production, as the fructose-5-phosphate molecules are 
recycled back to glucose-6-phosphate by transaldolase and transketolase. NADPH also may be synthesized 
by malic enzyme oxidation of malate to pyruvate. NADPH is the major cofactor used in cellular reductions 
and is used especially frequently by detoxification enzymes like NQO1, P450s, and GSTs. Furthermore, 
Nrf2-dependent genes function together to detoxify superoxide, and meanwhile to prevent Fenton chemistry 
on the SOD-produced intermediate H2O2. This occurs by two methods. First, ferretin sequesters free iron by 
binding it in the ferric form. Second, catalase, thioredoxin, and peroxiredoxins reduce H2O2 to water. Thus, 
Nrf2-driven genes reduce superoxide to water and prevent production of hydroxyl radicals. 
 [Modified from Lee JM et al., 2003]. 
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Figure 2. General scheme for the induction of gene expression through the Keap-Nrf2-ARE 
signaling pathway. Small molecules of endogenous and exogenous origin lead to activation of Nrf2-
regulated genes. These agents disrupt the association of Nrf2 with Keap1,leading to diminished rates of 
proteolysis of Nrf2 and enhanced nuclear accumulation. Phosphorylation of Nrf2 by a series of kinases 
also affects its fate and distribution. Interaction of Nrf2 with other transcription factors and proteins of the 
transcriptional complexallows for transactivation of ARE-responsive genes. Induction of these genes, 
wich include prototypic coniugating and antioxidative genes, results in an adaptive response that 
enhances te resistance of cells to environmental stresses mediated electrophiles and free radicals. 
[Modified from Ferraiuolo L et al., 2011] 
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Experimental section 
 
 
Nrf2-ARE pathway as an attractive target for neuroprotection in 
ALS: identification of small molecule activators of Nrf2-mediated 
transcription in two libraries of drugs 
 
Mounting evidence suggests that ALS is not simply an event that occurs within 
neurons, distinct from influence by surrounding cells. This concept may be best illustrated 
in the context of the familial form of ALS, in which several groups have found major 
astrocyte and microglial involvement in disease progression. Researchers studying this 
disease have found that expression of the mutated allele in astrocytes alone is sufficient to 
cause motor neuron degeneration in vitro (Nagai M et al., 2007, Vargas MR et al., 2006). 
Furthermore, knocking down expression of the mutated allele in astrocytes leads to 
diminished microglial activation and overall disease progression (Yamanaka K et al., 
2008). The mechanism by which astrocyte dysfunction leads to neural degeneration in ALS 
was explored by Barbieto (Barbieto LH et al., 2004). Several potential routes exist by 
which reactive astrocytes may potentiate neurodegeneration, including downregulation of 
glutamate transporters, release of reactive nitrogen species, or active release of 
proapoptotic proteins such as Fas-ligand or NGF. Thus, targeting non-neuronal cells may 
be a valuable option for therapeutic intervention, not only to prevent toxicity mediated by 
glia, but also to stimulate glial protective responses. Interestingly this hypothesis has been 
extended and tested in cell culture by using the ALS model with Nrf2 as a protective agent. 
The therapeutic potential of Nrf2 was explored in a model of ALS in isolated astrocytes 
from mice overexpressing the gene coding for superoxide dismutase-1 that was mutated 
from glycine to alanine at position 93 (G93A-SOD). Wild-type motor neurons were plated 
on top of the astrocytes. It was previously found that this co-culture scheme leads to motor 
neuron apoptosis that is not observed when the astrocytes were derived from wild-type 
mice (Vargas MR et al., 2006). The investigators coupled this knowledge to the 
observation that astrocyte-induced apoptosis in similar systems could be mediated by NGF 
and nitric oxide (Pehar M et al., 2004) and hypothesized that decreasing reactive nitrogen 
species could rescue the motor neurons. Follow-up experiments showed that activation of 
Nrf2 in the G93A-SOD–containing astrocytes was able to prevent apoptotic signaling 
(Vargas MR et al., 2006). 
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Based on this data, the multifaceted response of Nrf2 makes it an attractive target 
for prevention of neurodegeneration in ALS, and its activation in astrocytes may rescue 
motor neurons from death.  
For these reasons, during the period I spent at the SITraN in United Kingdom, I 
screened two libraries of small molecules on different reporter cell lines in order to identify 
activators of Nrf2-mediated transcription. The cell lines I used were CHO cells and C6 
cells, both cell lines were efficiently used in a previous library screening conducted in the 
SITraN laboratories. The two libraries I screened were from two different commercial 
sources, Tocris and Prestwick libraries, and each of them was composed of almost 1000 
molecules.  
Most of the molecules from Prestwick are already used in human therapy and are 
employed in different pathologies, but their activity on Nrf2-ARE pathway is unknown. 
Moreover, many molecules in this library have known human safety data as they are that 
did not make it to clinic. This can be simply because they were no better than other drugs 
on the market rather than negative reasons.  
Tocris library is designed to identify pathways, as it has inhibitors and activators 
of known pathways. As for molecules from Prestwick library, also the activity of Tocris 
molecules on Nrf2-ARE pathway is unknown.  
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Materials and Methods 
 
Cell Culture 
Chinese Hamster Ovary (CHO) and C6 (rat) astrocyte cell lines were routinely 
maintained in DMEM supplemented with 10% FCS and penicillin/streptomicyn. The ARE-
TK-GFP and the TK-GFP reporter constructs were a kind gift of the laboratory of cancer 
research of the University of Wisconsin. The TK-EGFP reporter construct consists of a 
123bp thymidine kinase promoter inserted in the multiple cloning site of pEGFP and the 
ARE-TK-EGFP also contains 4 repeats of a 41bp GST ARE motif 3’ to the TK promoter. 
These plasmids were transfected into CHO and C6 cell lines and after selection in 0.5 
mg/ml G418 they were expanded and selected for basal expression using fluorescence 
activated cell sorting (BD, FACSAria). These mixed populations of stable transfectants 
with basal eGFP expression were used in subsequent assays and designated 4xARE-TK-
GFP for the ARE containing line and TK-GFP for the control cell line. 
 
Andrographolide EC 10, EC 50 and EC 90 determination  
Andrographolide is a diterpen lactone and the principal active component in 
extracts of the herb Andrographis paniculata, which is widely used in Indian herbal 
medicine as an anti-infective, anti-inflammatory and hepatoprotective agent. From a 
previous library screening conducted in the SITraN laboratories, andrographolide was 
identified as an activator of the Nrf2-ARE pathway in CHO and C6 cells. For these reason 
andrographolide was used as positive control that represented our current best and its 
EC10, EC50 and EC90 on CHO and C6 transfected cell lines was determined. 
 
ARE reporter assay-library screening validation 
In order to screen the two libraries of 2000 small molecules the TK-GFP CHO 
ARE reporter cell line and the TK-GFP C6 ARE reporter cell line were subjected to a Z’ 
score assay in a 384 well plate using different methods of seeding and treating ("z' score 
determination based on "Assay Validation", Eli Lilly and Company and the National 
Institutes of Health Chemical Genomics Center). In brief, 15,000 cells/well were seeded in 
a 384 well plate and after 24 hours alternate wells were incubated with andrographolide at 
different concentrations corresponding to its EC90, EC50 and EC10 respectively. GFP 
fluorescence (ARE induction) was then measured at Ex485/Em530 using a fusion plate 
reader (Packard Bioscience). The Z’ score was calculated as follows: 
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Acceptable Z’ scores were >= 0.4 
The Z’ score assay was performed for both the CHO and C6 transfected cell lines. 
 
Library screening 
For the library screening, CHO and C6 transfected cell lines were plated at a 
density of 15000 cells for each well in a 384 multiwell in normal DMEM containing 10% 
FBS on day -1 and on day 0, media was replaced and cells were incubated for 24 hours 
with drug (1 compound/well). The cell seeding was performed using the cell dispenser 
Matrix Control Mate, (Thermo Scientific). After the seeding, drugs were delivered to the 
assay using the Echo® Liquid Handling System (Labcyte Inc., USA). Echo® 550 was able 
to dispense the compounds directly from the 96 well of the library through the use of 
acoustic energy to transfer liquids. Sound waves ejected precisely-sized droplets from the 
source liquid into the 384 well plate suspended above the source. The Echo liquid handling 
platform used no tips, pin tools, or nozzles, so there was no contact between the instrument 
and the liquid. The Drop transfer volume for Echo® is 2.5 nL and the volume transfer 
range is 2.5 to 10,000 nL (source-plate specific), moreover its transfer accuracy is <10% of 
the deviation from target volume. Echo® 550 offered many advantages in respect to hand 
pipetting, indeed we could deliver tiny volumes, maximize the use of the library and limit 
contaminations of our cells. 
GFP fluorescence (ARE induction, Ex 485nm/Em 530) were then measured. The 
TK- GFP CHO ARE cell line was tested twice in a single point assay at 10µM, and once at 
500nM.  
The control TK-GFP CHO cell line was screened once at 10µM and once at 
500nM to eliminate false positives. 
 
ARE reporter assay-determination of EC 50 
Reporter assays were run as for the library screen with a concentration curve 
raging from 0.001-100uM in triplicate in normal DMEM for 24 hours. Non linear 
regression was used to fit sigmoid dose-response curve on a semi-Log plot to calculate the 
EC50 using Graph Phad Prism (Graph Pad Software). The reporter assay was performed 
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similarly in CHO an C6 cell lines stabily transfected with 4xARE-TK-GFP and TK-GFP 
constructs. 
 
Results 
 
Andrographolide EC 10, EC 50 and EC 90 determination  
From a previous library screening conducted in the SITraN laboratories, 
andrographolide was identified as an activator of the Nrf2-ARE pathway in CHO and C6 
cells. For this reason, in this study andrographolide was used as positive control that 
represented our current best and its EC10, EC50 and EC90 on CHO an C6 cell lines stably 
transfected with 4xARE-TK-GFP was determined. 
As reported in Figure 1, andrographolide showed similar activity on both C6 and 
CHO cell lines (C6 EC50=1.8±0.2µM; CHO EC50=1.4±0.15µM). 
 
-12 -10 -8 -6 -4 -2
0
5000
10000
15000
20000
25000 EC10= 0.31±0.03M
EC50= 1.8±0.2M
EC90= 10.5±1.0M
EC10= 0.4±0.038M
EC50= 1.2± 0.10M
EC90= 3.5±0.4M
C6
CHO
log10 [compound]
G
F
P
 f
lo
u
re
s
c
e
n
c
e
 (
R
F
U
)
 
 
Figure 1. Data obtained by three different experiments carried out in duplicate. Data are shown 
as mean values ± SEM. 
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ARE reporter assay-library screening validation 
 The Z’ score assay was performed in order to determine working conditions of 
confidence and reproducibility necessary to perform the drug screening. Although we set 
the assay up with a known activator with a dose response already determined, using a 
single dose assay we had a good chance of identifying a positive response. 
The drug screen logistically had to be done at a single dose, therefore it was 
unlikely that the hits would have been at optimal dose, so we simply needed to know at a 
dose that we could identify any activation, not simply good activation. Even more, we did 
not consider any difference between hits until we did the secondary assays of dose 
response, however big or little the response in the primary screen, they were simply above 
or below the threshold set by us. 
The Z' score determination was run using different combined methods, as reported 
in table 1 and 2. The best Z' score determined for the CHO cells was equal to 0.773; the 
best Z' score determined for the C6 cells was 0.300. Both these Z' scores were obtained 
using a cell dispenser for the seeding and the Echo® Liquid Handling System for the 
treatments. 
 
CHOcells Seeding Teatments Z score 
1
st
  By hand  By hand  2,153  
2
nd
  Cell dispenser  Plate mate  0,681  
3
rd
 Cell dispenser  Echo  0,473  
 
Table 1. 
 
C6 cells Seeding Treatments Z score 
1
st
  By hand  By hand  0,077  
2
nd
  Cell dispenser  Plate mate  0,490  
3
rd
 Cell dispenser  Echo 0,300  
 
Table 2. 
42 
Library screening and reporter assay validation 
In order to screen the two libraries of compounds, Nrf-2-ARE reporter cell lines 
were generated in Chinese hamster ovary (CHO), the libraries were screened twice with 
compounds at 10 µM and once at 500nM, in both the reporter and control cell lines. 
For the 10 µM, we used a single dose assay and we identified every positive 
response, baring in mind it could be well out of its ideal range.  
A good concentration for a drug is usually in the nanomolar range; this can limits 
the side effects and avoid the aspecific binding to other receptors or molecules.  
Our screening was performed at a higher concentration than nanomolar 
concentration, but as previously explained, the drug screen logistically had to be done at a 
single dose, therefore it was unlikely that the hits would have been at optimal dose, so we 
simply needed to know at a dose that we could identify any Nrf2-ARE pathway activation, 
not simply good activation. 
The approach we used in this work was the “fast track“ approach, whereas in a 
normal clinical trial it’s necessary to optimize leads by chemical modification. Obviously, 
we wouldn’t be adverse to optimization, but it is more expensive and requires more time. 
As a second step, we repeated the screening also at 500 nM in order to see if we 
had missed some very good hits that might show toxicity at 10 µM. Using this method we 
found the compound 14P for the Prestwick library and that we had missed in the previous 
screening at 10 µM. Moreover, using the results from the 500 nM screening, for the Tocris 
library we could reduce the number of compounds to test and so that of assays (i.e. dose-
response curves) to perform because of time constraints.  
In the end, a total of 14 compounds (1P-14P) from the Prestwick library and 21 
compounds (1T-21T) from the Tocris library were identified as hits (positive response in 
both the 10 µM screenings and/or in the 500nM screening, no false positive response in the 
control cell line and no evidence of toxicity). 
The selected compounds (hits) from both the libraries were assessed in full 
concentration response curves in the same assay.  
In Figure 2 the dose-response curves for the 14 hits from the Prestwick library are 
reported. As shown in Figure 2, compounds 3, 11, 9 and 12 didn’t fit the curve, so they 
were excluded from the next screening. 
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Figure 2. Dose-response curves on CHO cells for the 14 hits from the Prestwick library. Data 
obtained by three different experiments carried out in triplicate. Data are shown as mean values ± SEM. 
 
Seven of the twenty-one hits identified from the Tocris library screening showed 
background fluorescence (due to compound autofluorescence) on control cells when tested 
at higher concentrations (>10 µM), so they were excluded from the next screening. 
In Figure 3 the dose-response curves for the 14 hits remaining from the Tocris 
library are reported. 
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 Figure 3. Dose-response curves for the 14 hits remaining from the Tocris library; seven of the 
twenty-one hits identified from the Tocris library screening were excluded from the next screening because 
they showed background fluorescence when tested at high concentrations. Data obtained by three different 
experiments carried out in triplicate. Data are shown as mean values ± SEM. 
 
In order to determine whether the selected hits were able to induce activation of 
the Nrf2-ARE pathway also in cells that correlate directly with the ALS diseases, the best 
hit molecules were screened in C6 astrocytic cells stably transfected with the Nrf2-ARE 
construct. 
Ten Prestwick library molecules identified as hits from the previous screening 
(dose-response curve on CHO cells) were selected and tested for the dose-response curve 
on C6 cells. The ten selected molecules were those that fitted the curve or that showed a 
good dose-response activity on CHO cells. As reported in Figure 4, the molecules that 
showed the best activity on Nrf2-ARE pathway in C6 cells were the compound 2P 
(EC50=209.4±30 nM) and the compound 14P (EC50=412.1±40 nM). Indeed, both these 
molecules were able to induce the activation of the Nrf2-ARE pathway at a 10x times 
lower concentration than the reference compound andrographolide (EC50=1.8±0.2µM). 
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Figure 4. Dose-response curve on C6 cells of ten Prestwick library hits selected from the 
previous screening on CHO cells. Data obtained by three different experiments carried out in triplicate. Data 
are shown as mean values ± SEM. 
 
Moreover, seven hits from the previous screening on CHO cells of the Tocris 
library were selected following the same criteria used for the Prestwick library. These 
molecules were tested on C6 cells and a dose-response curve was determined. 
As shown in Figure 5, the molecules 1T, 5T, 2T and 11T showed a good activity 
on Nrf2-ARE pathway in C6 cells and their EC50 values were 4.4±0.4 µM, 4.4±0.45 µM, 
5.8±0.5 µM, 5.2±0.5 µM respectively. Unfortunately no one of them showed higher 
activity than andrographolide, but their EC50 values are still quite good and comparable 
with that of andrographolide itself. 
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Figure 5. Dose-response curve on C6 cells of seven Tocris library hits selected from the 
previous screening on CHO cells. Data obtained by three different experiments carried out in triplicate. Data 
are shown as mean values ± SEM. 
 
 
Discussion 
 
Pathogenic mechanisms underlying ALS are not fully understood. Evidence from 
model systems, and from ALS patients, provides strong evidence for a role of oxidative 
stress in disease phatogenesis (Barber SC et al. 2006). 
Oxidative stress has significant crosstalk with other potential mechanisms of 
neuronal injury, including mitochondrial dysfunction, excitotoxicity, protein aggregation 
etc. More importantly it can feed into these mechanisms or be enhanced by them. 
Despite the central role, therapeutic targeting of oxidative stress in ALS has failed 
to translate into clinical benefit for patients. This may be due in part to the lack of 
sufficiently potent anti-oxidants able to penetrate the CNS (Barber SC et al. 2006). An 
alternative novel approach to limiting neurodegenerative disease is to promote activation 
of the transcription factor Nrf2. 
1T 
5T 
2T 
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The key objective of this program of work was to identify molecules that could be 
fast-tracked for clinical testing in ALS, having been used previously in humans, as those of 
the Prestwick library or designed to identify new pathways, as those of the Tocris library. 
With this data, some interesting molecules from both the libraries were identified, 
as shown by their EC50 concentration values determined on activation of Nrf2-ARE 
pathway in C6 cells. 
Two molecules were selected from the Prestwick library, and four molecules were 
selected from the Tocris library. 
In particular the molecules 2P and 14P were able to induce the activation of the 
Nrf2-ARE pathway at a 10x times lower concentration than the reference compound 
andrographolide (EC50=1.8±0.2µM). 
Because fast track was used we cannot optimize the hits further chemically, or 
else these would need further safety trials. Indeed, modification of a known safe molecule 
needs re-testing (i.e. pre-clinical and clinical trials) as we have a new molecule. On the 
other hand, this consideration gives us the possibility to have already useful information 
about their activity and safety in humans. We could affirm that, using the fast track 
approach, we are able to save on the costly human trials for safety, but we possibly could 
be sub-optimal on compounds potency. The fast track approach is a good approach to proof 
of target, but then it often requires investments to find a better hit of the pathways 
identified. 
The compound 2P, for example is used in alcohol abuse and recent in vitro studies 
on breast cancer cell lines evidenced its good anticancer activity. The compound 2P has no 
significant side effects; meanwhile the compound 14P can cause nausea, loss of appetite 
and stomach cramps. The compound 14P is used as antirheumatic and its effects on other 
pathologies or pathways were not been investigated before.  
Such as the Prestwick compounds, also the Tocris molecules were well known to 
act on pathways and receptors different from Nrf2, such as the valinoid receptor, the µ-
receptor of morphine or the 5HT release, but not on the Nrf2-ARE pathway. It’s important 
to highlight that, differently from the Prestwick hits already used in therapy, the Tocris 
ones primarily tell us about Nrf2-pathway activation and understanding novel pathways 
that could be a therapeutic target in neurodegenerative diseases. 
Further investigations, as in silico assays, are necessary in order to determine 
chemical and physical characteristics (LogP, PSA etc) of some of the selected molecules. 
Moreover, to confirm that these “lead inducers” are able to activate the Nrf2-ARE 
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pathway, quantitative RT-PCR for Nrf2 target genes, as NADPH quinine oxidoreductase 1 
(NQO1) are necessary in C6 cells. 
Another interesting aspect to investigate is the ability of these molecules to 
activate the Nrf2-ARE pathway on human cells. Unfortunately, due to time constrain, I 
couldn’t test the hit molecules from both libraries on a human astrocytic cell line 
(1321N1), but experiments conducted on this cell line could give important information on 
the molecules activity in a human cell type. 
 
 
 
NOTE: 
In order to do not preclude the possibility of a patent on some of these molecules, 
I couldn’t show the names and the molecular structures of the compounds tested in this 
thesis. 
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Chapter 4: Glioblastoma multiforme I 
 
Matrix Metalloproteinases 
 
The Matrix Metalloproteinases (MMPs) family consists of more than 25 
structurally related, zinc-dependent endopeptidases that are secreted in the zymogen, or 
inactive, form. So far, 23 human MMPs have been identified and divided into subgroups 
based on their structure and substrate specificity: collagenases, gelatinases, 
stromelysins, matrilysins and membrane-type MMPs (MT-MMPs). In the active form 
they are capable of degrading various components of the extracellular matrix (ECM) 
(Nagase H and Woessner JF Jr, 1999, Vihinen P and Kähäri, VM 2002). The proteolytic 
degradation of the ECM, the alteration of the cell-cell and cell-ECM interactions, and 
the migration of cancer cells through the basement membrane are the main problems in 
tumour progression (Cauwe B et al., 2007, Heino J, 1996; Konstantinopoulos PA et al., 
2008, Plate KH et al., 1994, Tonn JC et al., 1999). Moreover, some MMPs have been 
demonstrated to be upregulated in many tumours and have become attractive targets for 
anti-tumour drug development (Brown PD and Giavazzi R, 1995, Lein M et al., 2000, 
Rabbani SA et al., 2000). Among the members of the MMP family, the gelatinases, 
MMP-2 (gelatinase A) and MMP-9 (gelatinase B), are thought to play a key role in 
degradation of type IV collagen and gelatin, the two major components of ECM. 
Increased expression of MMP-2 and MMP-9 is reported in many human tumors, 
including ovarian, breast and prostate tumors, and melanoma (Roomi MW et al., 2003).  
Elevated levels of MMP-2 and MMP-9 have also been found in human 
glioblastoma tissue samples, compared with low-grade brain tumors and normal brain 
tissue (Rao JS, 2003).  
In particular, MMP-2 is highly expressed in gliomas and both mRNA and 
protein levels increase along with tumor progression and grade (Kargiotis O et al., 
2008). It has been shown that MMP-2 is localized in both tumor and vasculature cells, 
thus indicating multiple roles for this enzyme in tumor progression, including 
angiogenesis (Forsyth PA et al., 1999). MMP-2 expression is also known to be 
associated with tumor invasion and metastasis (Komatsu K et al., 2004). 
On these bases, the two gelatinases MMP-2 and MMP-9 can be considered one 
of the prime factors in glioma invasiveness, and their expression correlates with the 
progression and the degree of malignancy of gliomas (Forsyth PA et al., 1999, Kim SY 
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et al., 2008). Unfortunately, in the past, the clinical development of MMP inhibitors 
(MMPIs) has been very problematic, because these drugs, often with a broad spectrum 
of activity, produced dose-limiting musculoskeletal toxicities (Whitaker M et al., 1999). 
Indeed, it is important to emphasize that not all MMPs contribute to tumour 
progression. Recently, it has been demonstrated that some MMPs are involved in innate 
immunity and host defence against cancer, others inhibit tumour growth and malignant 
transformation, and others exert antiangiogenic effects (Konstantinopoulos PA et al., 
2008). In particular, inhibition of MMP-1 and MMP-14 has been hypothesized to be the 
cause of the muskoloskeletal syndrome (MSS) observed clinically with broad spectrum 
inhibitors, while MMP-8 (López-Otín C et al., 2009) and MMP-3 (Overall CM et al., 
2006) were demonstrated to have anti-tumor properties and their inhibition may be 
counterproductive.  
Hence, both the side effects and the poor outcome due to wide inhibition of 
MMPs could be avoided by the use of selective MMP-2 and MMP-9 inhibitors. 
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Experimental section 
 
 
Matrix Metalloproteinases inhibitors 
 
The inhibition of MMP activity represents a promising non-cytotoxic approach 
to glioma treatment. Almost all MMPIs are based on a chelating moiety interacting with 
the catalytic zinc ion and a hydrophobic portion protruding into the hydrophobic S1’ 
subsite, which is a deep pocket situated in proximity to the catalytic zinc ion. These 
compounds behave as competitive inhibitors since the zinc-binding group (ZBG) 
binding mode can mimic one of the transition states occurring during the substrate 
hydrolysis (Nuti E et al., 2009). 
Widely utilized ZBGs include: hydroxamic acids, carboxylic acids, pyrones 
(Puerta DT et al., 2005) and pyrimidinetriones. The most used of these is the 
hydroxamate group since it has excellent chelating properties (Nuti E et al., 2009, Flipo 
M et al., 2009)  
Unfortunately, clinical trials with MMPIs in cancer patients conducted over the 
past years failed to show a significant therapeutic response, mostly because the majority 
of patients enrolled had advanced metastatic disease (Coussens LM et al., 2002). 
Moreover, most of these clinical trials were carried out using broad-spectrum MMPIs, 
such as marimastat 1 (BB2516) (Beckett RP et al., 1996), prinomastat 2 (AG3340) 
(Sorbera LA 2000) and CGS27023A (Levitt NC et al., 2001) 3 (Figure 1), and thus 
produced undesired side effects. 
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Figure 1. Broad spectrum MMP inhibitors used in clinical trials for cancer. 
 
In vitro studies focusing on marimastat demonstrated significant inhibition of 
invasion in glioma cell lines, suggesting that MMPIs may have a role in the treatment of 
gliomas (Tonn JC et al., 1999). Unfortunately, in vivo marimastat did not improve 
survival in patients with glioblastoma following surgery and radiotherapy if used as 
single agent (Levin VA et al., 2006). Furthermore, the use of broad spectrum MMPIs in 
clinical trials has been greatly limited by muskoloskeletal side effects, which imply a 
reduction of the dose, and consequently also a reduction of beneficial effects 
On the basis of these considerations, the aim of this work was to identify new 
compounds that could selectively inhibit gelatinases without significantly affect other 
MMPs and that can be potentially useful as antiglioma agents.  
In this chapter, the biological characterization of new MMP-inhibitors is 
reported. In the first part of this chapter (section 4.1), the attention has been directed 
towards a new class of MMP-2 inhibitors belonging to the recently identified family of 
N-O-isopropyl sulfonamide hydroxamates (Nuti E et al.,2009; Rossello A et al., 2004, 
2005), which have shown potent inhibition of MMP-2 activity in in vitro test tube 
assays, and have been demonstrated to inhibit the invasiveness of the fibrosarcoma cell 
line HT1080 (Rossello A et al., 2004). Two of these MMP inhibitors N-O-isopropyl 
sulfonamido-based hydroxamates (compound 1 and 2) were tested at nanomolar 
concentrations to investigate their potential efficacy in inhibiting the invasiveness and 
the proliferation of the human glioma cell line, U87MG. As a first step, the two 
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compounds at nanomolar concentrations were assayed on their ability to inhibit MMP-2 
cleavage of gelatin. Moreover, the MMP-2 expression was assessed following MMP 
inhibitor cell treatments. In order to help the development of multitarget therapies 
against GBM, the combined treatment of the U87MG glioma cells with the MMP 
inhibitors and the conventional chemotherapeutic drug TMZ was evaluated. 
In the second part of this chapter (section 4.2) has been described the biological 
evaluation of a new series of 4-butylphenyl(ethynylthiophene)sulfonamido-based 
hydroxamates, 4-7, synthesized in the laboratory of Prof. Rossello at the University of 
Pisa. Previous studies on carboxylate MMP inhibitors (Tamura Y et al., 1998, Kiyama R 
et al., 1999) had shown that the presence of an elongated hydrophobic substituent in P1’ 
like 4-butylphenylethynylthiophene could ensure a good activity toward gelatinases, 
sparing other enzymes like MMP-1, -3 and -7. In fact, gelatinases have a deep S1’ 
pocket while MMP-1 and MMP-7 present a shallow pocket in the catalytic site. For this 
reason, Rossello and his collaborators chose to maintain this type of substituent in the 
sulfonamido moiety and to change the ZBG in an effort to improve the selectivity also 
over other deep-pocket MMPs, such as MMP-8 and -3. In fact, as previously shown 
(Rossello A et al., 2005) selectivity of action against some deep-pocket MMPs can also 
be dependent on the nature of the ZBGs, that have different chelating geometries and 
different pKa.  
Moreover, starting from the simple, un-substituted secondary sulfonamide 4, 
derivatives 5a-d bearing various (R) aryl-alkyl chains in position α of the hydroxamate 
were synthesized by Rossello and his collaborators according to the hypothesis that the 
selectivity profile could be also affected by the presence and structure of the α-chain (P1 
group), as previously observed by Hanessian et al. (2001). The scaffold was further 
stiffened up by introducing α-chains fused with the sulfonamido moiety, thus affording 
cyclic compounds 6 and 7 (Figure 2).  
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Figure 2. Evolution of the new 4-butylphenylethynyl-thiophene derivatives scaffold. 
 
In this section the effects of these substitutions on MMP-2 and MMP-9 activity 
and selectivity have been described. First, the reported compounds were examined in 
vitro by fluorometric assay on isolated enzymes. The compounds 5a-d, 6, 7 were then 
tested for their ability to inhibit in vitro invasion of U87MG glioma cells through 
matrigel and to inhibit cell growth.  
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4.1 Inhibition of metalloproteinases derived from tumours: new 
insights in the treatment of human Glioblastoma 
 
 
Matherials and Methods 
 
MMP inhibitors: “in tube” activity 
The N-O-isopropyl sulfonamido-based hydroxamates MMP inhibitors, 
compounds 1, 2 and the standard MMP inhibitor belonging to the classical tertiary 
sulfonamido-based hydroxamates family (CGS_27023A) were synthesised as reported 
by Rossello et al. (2004) and Mc Pherson et al., (1997), respectively. All compounds 
were solubilized in dimethyl sulfoxide (DMSO). The ability of compounds to inhibit 
activity of human recombinant MMP enzymes on synthetic peptide substrates was 
performed as previously described (Rossello et al., 2004, Rossello et al., 2005) and 
reported as compound concentration able to inhibit the 50% of enzyme activity. 
 
U87MG cell line culture 
U87MG cells: see chapter 3. 
 
MMP inhibitors: cell derived MMP-2 activity tested on natural 
substrate 
In order to evaluate the inhibition of MMP-2 activity exerted by compounds 1, 
2 or CGS_27023A, the serum-free medium from cells was collected, centrifuged to r 
move the cell debris and the supernatant was incubated with IC50 dose compounds 1, 2 
or CGS_27023A for 3h. Gelatin zymography was performed as previously described by 
Wang et al., (2005) and Lim et al., (2009) with minor modification. Briefly, 2 μg of 
protein from each sample were mixed with the 5X-sample buffer (50mM Tris–HCl, 2% 
SDS, 0.1% bromophenol blue, 15% glycerol) and electrophoresed on 10% denaturing 
sodium dodecyl sulfate (SDS) polyacrylamide gels containing 1 mg/ml of gelatin. After 
electrophoresis, the gel was washed twice for 30 min in 2.5% Triton X-100 and 
incubated for 19 h at 20°C in 50mM Tris HCl (pH 7.5), 10mM CaCl2, 150mM NaCl 
and Briji 35 0.05%. The gel was stained with Coomassie Brilliant Blue R-250 (0.25% 
Coomassie Brilliant Blue R-250, 50% methanol, 10% acetic acid in H2O) and then 
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destained (30% methanol, 10% acetic acid in H2O). The MMP-2 activity was 
discernible by clear bands of gelatin digestion on a blue background and was quantified 
by using a densitometric image analysis software (ImageJ, National Institutes of Health, 
Bethesda, Maryland, USA). 
 
MMP inhibitors: effect on cell derived MMP-2 expression 
In order to evaluate MMP-2 expression, the 24 h treated and untreated adherent 
cells were lysed and used to evaluate MMP-2 mRNA levels by the means of real-time 
polymerase chain reaction (real-time PCR). Moreover, the serum-free medium from 
treated and untreated cells was collected and employed to detect MMP-2 protein level 
by the means of enzymelinked immunosorbent assay (ELISA). The relative 
quantification of MMP-2 gene expression was evaluated as previously described (Papi 
A et al., 2007). In brief, total RNA was isolated using Rneasy® Mini Kit and reverse 
transcribed in cDNA with Quantitect® reverse transcriptase. Real-time PCR was 
performed by using Brilliant® II SYBR® Green. The MMP-2 mRNA levels for each 
sample were normalised against β-glucuronidase (GUSB) mRNA levels, and relative 
expression was calculated by using Ct value. The primer sequences were: 
 
 MMP-2 forward, 5’-CTGAAGGACACACTAAAGAAGATG-3’; 
 MMP-2 reverse, 5’-GGAAGGCACGAGCAAAGG-3’; 
 GUSB forward, 5’-TGGTATAAGAAGTATCAGAAGCC-3’; 
 GUSB reverse, 5’-GTATCTCTCTCGCAAAAGGAAC-3’. 
 
The MMP-2 protein levels was determined in duplicate using the RayBio® 
Human MMP-2 ELISA kit designed to measure its pro and active forms, according to 
the manufacturer's instructions. Specimens were incubated with an enzyme substrate 
and 3,3',5,5'- tetramethylbenzidine for the development of colour, that was analyzed 
using an ELISA plate reader (Wallac Victor 2, 1420 Multilabel Counter, Perkin-Elmer) 
at 450 nm. The peroxidase activity was proportionate to the amount of antigen in the 
specimens, determined according to a standard curve. The minimum detectable dose of 
MMP-2 was less than 3.5 ng/ml. The intraassay and inter-assay CV were <10% and 
<12%, respectively. 
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MMP inhibitors: effect on cell proliferation 
Cell proliferation was estimated by the colorimetric MTS conversion assay 
(Cell Titer 96® Aqueous One Solution Cell Proliferation Assay, Promega), as 
previously reported (Chelli B et al., 2004). Cells were seeded at 10,000 cells/cm2 in 
completed medium at 37°C and 5% CO2. After overnight, the cells were incubated for 
24 h with DMSO (control sample) or with test compounds, MTS reagent was added, 
and the absorbance of individual wells was measured with a microplate reader (Wallac 
Victor 2, 1420 Multilabel Counter, Perkin-Elmer). 
Each compound concentration was tested in duplicate, and the experiments 
were repeated at least three times. 
 
MMP inhibitors: effect on cell viability in the absence and in the 
presence of TMZ 
Cell viability was measured by the Trypan Blue exclusion assay, as previously 
reported (Ruan S et al., 1999). This assay was performed on U87MG cells treated with 
the tested compounds for 24 h (short-term treatment) and for several days (long-term 
treatment). Previously, in order to allow the adhesion of cells to the plates, the cells 
were seeded at 10,000 cells/cm2 (24 h short-term treatment) or at 3,000 cells/cm2 
(several days long-term treatment) in complete medium at 37°C and 5% CO2 for 24 h. 
Short-term treatment: the culture medium was replaced, the cells were 
incubated with DMSO (control sample) or with compounds 1, 2 or CGS_27023A and 
collected after 24 h. Long-term treatment: the culture medium was replaced, the cells 
were incubated with TMZ (50 µM or 100 µM) or DMSO (control sample) for several 
days (until to 16 days). On day 7, 1 ml of fresh complete medium was added with or 
without the compounds 1, 2 or CGS_27023A. The cells were collected at various times 
(1, 3, 7, 9, 13, 16 days). The collected cells were stained with Trypan Blue dye (0.4% 
solution in 0.9% NaCl), and counted in a haemocytometer chamber (Burker counting 
chamber). 
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MMP inhibitors: effect on cell invasiveness in the absence and 
in the presence of TMZ 
The chemotaxis and Matrigel invasiveness of U87MG cells were evaluated as 
previously described (Albini and Benelli, 2007). Matrigel basement membrane matrix 
(BD Biosciences), and 24 Transwell® (6.5 mm diameter 8.0 μm pore size polycarbonate 
filters, Costar, Corning, NY) were utilised. Several concentrations of Matrigel were 
tested to ascertain the best “invasive index”. In an optimal test, the number of invasive 
cells should be about 50% of the number of cells that migrated by chemotaxis alone. 
The best experimental conditions to evaluate the invasiveness of cells were the 
following: the surface of the transwell was coated with Matrigel (25 μl of a solution of 
0.32 mg/ml for each well) at room temperature overnight to form a genuine 
reconstituted basement membrane. The U87MG cells were suspended in serum free 
medium (60,000/400 μl) and added to the upper compartment of the transwell in the 
absence and in the presence of the compounds 1, 2 or CGS_27023A, while 200 μl of 
RPMI containing 10% foetal bovine serum was added to the lower compartment. The 
cells were allowed to invade through the matrices at 37 °C for 24 h. The number of 
invading cells was quantified by counting the cells on the lower surface of the transwell 
membrane after fixing with p-formaldehyde and staining with crystal violet. 
Nonmigrating cells on the upper surface were removed with a cotton bud. Pictures of 
randomly picked light microscope fields were taken (5 fields for each filter), and cells 
were counted using ImageJ (ImageJ Software, version 1.41o; USA). This method was 
also employed to evaluate cell invasiveness after TMZ treatments with or without MMP 
compounds. Each drug concentration was tested in duplicate, and the experiments were 
repeated at least three times. 
 
Data Analyses 
Statistical analyses were performed by one-way ANOVA (with post hoc 
Newman-Keuls test) by using the GraphPad Prism computer program (GraphPad 
Software, version 4.0; San Diego, CA). P value < 0.05 was considered statistically 
significant. All data are presented as the mean ± S.E.M., derived from at least three 
independent experiments done in duplicate. 
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Results 
 
The N-isopropoxy-biphenylsulfonamide hydroxamic acids 1 and 2 (Figure 3) 
were employed in cell treatment 
experiments.
 
 Figure 3. Structures of the MMP inhibitor compounds 1 and 2 used in this study. 
 
In test tube assays, nanomolar concentrations of compounds 1 and 2 resulted to 
selectively inhibit the activity of the human recombinant matrix metalloproteinases, 
MMP-2, MMP-9 and MMP-12. 
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The ability of the compounds to affect MMP-2 activity at such concentrations 
(12 nM compound 1, 1 nM compound 2 and 25 nM CGS_27023A) prompted us to 
investigate their ability to affect glioma cell parameters, such as viability, proliferation 
and invasiveness. As first step, the ability of compounds to affect MMP-2 derived from 
cells was assayed on gelatin natural substrate. 
 
MMP inhibitors: cell derived MMP-2 activity tested on natural 
substrate 
The serum-free medium from U87MG cells was collected, centrifuged, 
aliquoted and incubated without or with the compounds 1, 2, or CGS_27023A for 3 h; 
then the aliquots were subjected to zymography, as described in the method section. A 
decrease in gelatinolytic activity of MMP-2 was observed after treatment with the 
compound 1, 2 or CGS_27023A (Figure 4). 
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Figure 4. Effect of MMP inhibitor compounds 1, 2 and CGS_27023A on cell derived MMP-
2 activity: zymogram analysis of gelatinolytic activity. Following treatment with the compounds (12 nM 
compound 1, 1 nM compound 2 and 25 nM CGS_27023A), as described in experimental section the 
proteins were separated with 10% SDS-PAGE containing gelatin (1 mg/mL). The unstained bands 
corresponded to the areas of gelatin digestion (a typical result from a single experiment is shown). Band 
intensity was quantified by a densitometric image analysis software (ImageJ, National Institutes of 
Health, Bethesda, MD, USA), and data (bottom) are expressed as the percentage of treated samples with 
respect to untreated samples. Each bar represents the mean±SEM of three independent experiments; *** 
P_0.0001. 
 
MMP inhibitors: effect on cell proliferation 
 
The synthetic compounds did not affect cell survival at MMP inhibitor 
nanomolar concentrations, as shown in Figure 5. 
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Figure 5. Inhibition of the viability of U87MG glioma cells by MMP inhibitors. U87MG 
cells were treated with MMP inhibitors 1, 2 and CGS_27023A for 24 h. After incubation, cell viability 
was measured by the MTS conversion assay as described in the Materials and methods section. Results 
are expressed as a percentage of the MTS activity observed after treatment with the compounds (12 nM 
compound 1, 1 nM compound 2 and 25 nM CGS_27023A), compared to untreated control cells (100%), 
and shown as the mean±SEM. Data are obtained from at least three separate experiments done in 
duplicate. 
 
Specifically, the MTS activities of the cells treated with MMP inhibitors 
compared to control cells treated with the vehicle, DMSO, were 97.4%, 98.6% and 
99.2% for compounds 1, 2 and CGS_27023A, respectively. The Trypan Blue dye-
exclusion assay gave similar results (data not shown). 
 
MMP inhibitors: effect on cell invasiveness 
As shown in Figure 6, the U87MG cells treated with the synthetic MMP 
inhibitors showed a marked reduction in glioma cell invasion through the Matrigel 
membrane. In particular, the cells treated with compounds 1, 2 or CGS_27023A 
exhibited a significant reduction in invasion, equal to 50%, 48%, and 31% (p<0.001), 
respectively (Figure 6b). 
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Figure 6. Compounds 1 and 2 affect U87MG cell invasiveness. (a) Cell invasion was 
analysed using the Matrigel basement membrane transwell system as described in Materials and Methods. 
Cell migration was quantified by counting the number of cells that migrated into the lower surface of the 
transwell membrane. Images in the Figure panels show cells that migrated to the lower surface of the 
transwell membrane. The magnification was 200x. The migration of untreated cells is shown in the panel 
marked CTRL. The migration of the cells treated with compound 1, compound 2 or the standard, 
CGS_27023A is shown in panels labelled 1, 2 and CGS_27023A, respectively. (b) Treatment of cells 
with compound 1 (12nM) or 2 (1nM) for 24 h significantly reduced the invasiveness of glioma cells by 
50% and 48%, respectively. In the figure, significant reduction of cell invasiveness (31%) is also shown 
for treatment with the standard compound, CGS_27023A (25nM). The results are expressed as the mean 
value of the percentage of invasive cells observed after treatment compared to untreated control cells. *** 
Statistically significant result (P<0.01). 
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MMP inhibitors: effect on MMP-2 expression 
 
To determine whether the 24 h MMP inhibitor cell treatments were 
accompanied by an effect on MMP-2 expression, we analysed MMP-2 mRNA and 
protein levels by real-time PCR and ELISA, respectively. MMP-2 mRNA was reduced 
by 52%, 71% and 25% with respect to the control following cell treatments with 
compounds 1, 2 and CGS_27023, respectively (Figure 7a). The MMP-2 protein level in 
the serum-free medium from untreated U87MG cells was 10.4 ng/ml (at which 100% 
was attributed). The treatment for 24 h with compound 1, or CGS_27023A resulted in a 
47%, and 16% decrease of MMP-2 protein level (Figure 7b). The MMP-2 expression 
levels were not detectable (<3.5 ng/ml) following treatment with compound 2. 
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Figure 7. MMP inhibitors: effect on MMP-2 expression. The MMP-2 mRNA and protein 
levels were determined following 24 h cell exposure to CGS_27023A (25nM), compounds 1 (12nM) or 2 
(1nM) by the means of real-time PCR and ELISA, respectively. (a) Quantitative real-time PCR was 
performed in triplicate, and repeated twice. Results±SEM are expressed as the percentage of control; * 
P<0.05; *** P<0.0001. (b) ELISA was performed in duplicate, and repeated twice. Results_SEM are 
expressed as the percentage of control. MMP-2 protein level was reduced by 47% and 16% after 
treatment with the compound 1 and CGS_27023A, respectively. MMP-2 protein level after treatment with 
compound 2 was not detectable (<3.5 ng/mL). 
 
MMP inhibitors: effect on cell viability in the presence of TMZ 
First, we established the growth curves for untreated cells using two different 
growth conditions to optimize the cell culturing for treatments longer than 48 h. In the 
first experimental condition, to investigate the fate of glioma cells from 0 to 16 days, we 
seeded the U87MG cells in 1 ml of 10 % FBS medium and assessed the number of 
viable U87MG cells at various times using the trypan blue dye-exclusion method. In the 
second experimental condition, we added 1 ml of fresh complete medium on the 7th day 
after cell seeding. In the experiment carried out without addition of fresh medium, the 
number of viable cells increased until the 8th day, after which the viable cell number 
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significantly decreased. In the samples to which fresh medium had been added on the 
7th day, the cells showed transient growth arrest for one day, after which they 
proliferated until the 13th day and then lost viability. To assess proliferating cells, we 
chose to carry out the subsequent experiments with the addition of 1 ml of fresh 
complete medium on the 7th day of culture. The U87MG cells were incubated in the 
presence of DMSO or of two different TMZ concentrations (50 or 100 µM) and counted 
at different times after the treatment (from the 1st to the 13th day), using the trypan blue 
exclusion method. The data, shown in Figure 8, demonstrated that the TMZ treatments 
markedly reduced the number of human glioma cells, both at 50 µM and 100µM TMZ. 
 
 
 
Figure 8. Proliferation curve of U87MG cells treated with TMZ. Glioma cells were treated 
with 50 or 100 µM TMZ or with DMSO (control cells) and cultivated for 13 days. At various times, cells 
were collected and counted by using the Trypan Blue assay. Results are expressed as the number of viable 
cells per cm2 of surface. Data were obtained from at least three separate experiments done in duplicate (* 
P<0.05; *** P<0.0001). 
 
At the shortest time (1 day), TMZ did not affect cell viability; however, after 
three days, TMZ at 100 μM caused a significant reduction in viable cell number 
(P<0.05). The reduction in cell growth increased during longer treatments with TMZ 
(P<0.0001). Comparable results were observed for treatment with TMZ at 50 μM. 
We also evaluated cell death for each treatment and incubation time. After short 
incubation times, the difference between control cells and treated cells was less than 
10%, as verified by counting cells taking up trypan blue. After prolonged incubation 
times, the number of dead control cells did not exceed 20% of the total number of cells. 
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As we expected, when cells were treated with TMZ, the number of dead cells increased 
in a time dependent manner, ranging up to 40-50% of total cells on the 13th day (data 
not shown). Next, we examined the effect of treating cells with TMZ and compound 1 
or seventh day, we added 1 ml of fresh medium containing compound 1 or 
CGS_27023A to the TMZ-treated cells. The co-treated cells were collected at different 
times and counted using the trypan blue exclusion assay. The data for compound 1 or 
CGS_27023A co-treatments are shown in Figure 9. 
 
 
 
 
Figure 9. MMP inhibitors: effect on cell viability in the presence of TMZ. U87MG cells 
were treated with 50 or 100 µM TMZ and cultivated for 13 days. On the seventh day, 1 ml of fresh 
medium containing compound 1 or CGS_27023A to the TMZ-treated cells was added. At various times, 
cells were collected and counted by using the Trypan Blue exclusion assay. Results are expressed as the 
number of viable cells per cm2 of surface. Data were obtained from at least three separate experiments 
done in duplicate (* P<0.05; *** P<0.0001). 
 
The cell growth curves established with the TMZ alone treatment and with the 
combination of TMZ and the MMP inhibitor 1 or CGS_27023A did not show any 
differences in cell proliferation. Both the cell treatments completely inhibited cell 
growth compared to the control (P<0.0001). As evidenced in the experiment with TMZ 
alone, in the cells co-treated with TMZ and MMP inhibitors, the percentage of blue cells 
increased in a time-dependent manner, up to 50-60% of the total cell number at the 13th 
day of treatment (Figure 9). The same experiments were repeated using compound 2, 
and the results were comparable to those obtained for compound 1 (data not shown). 
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MMP inhibitors: effect on cell invasiveness in the presence of 
TMZ 
We studied whether the TMZ-MMP inhibitor co-treatment was able to suppress 
the invasive capacity of the U87MG cells. The results, shown in Figure 10, 
demonstrated that the co-treatment inhibited the number of cells invading through the 
Matrigel compared to the control. 
 
 
Figure 10. Glioma cell invasion through the reconstituted Matrigel basement membrane. 
U87MG cells were treated with TMZ or TMZ and compound 1 or compound 1 alone (12nM). The 
invasion assay was carried out as described in the Materials and methods section. Results are expressed as 
a percentage of invasive cells observed after treatment compared to untreated control cells (100%) and 
shown as the mean±SEM. Data are obtained from at least three separate experiments done in duplicate 
(*** P<0.001). 
 
Quantification indicated that in TMZ-treated cells, invasion was similar to that 
in control cells. In contrast, the cells co-treated with TMZ and the MMP inhibitor 1 
showed a marked reduction in glioma cell invasion to 50% of the control (P<0.001). 
The combination of TMZ and MMP inhibitor 1 evidenced the same effect 
obtained with inhibitor alone. The same experiments were repeated using compound 2, 
and the results were comparable to those obtained for compound 1 (data not shown). 
 
 
 
 
69 
Discussion 
 
In the present chapter section I reported the investigation of the potential 
anticancer activity of MMP inhibitor N-O-isopropyl sulfonamidobased hydroxamates 
(compounds 1 and 2), on the human glioblastoma cell line. Compounds 1 and 2 were 
chosen because they resulted, at nanomolar concentrations, potent inhibitors of MMP-2 
activity against the synthetic peptidic substrate (IC50=12 nM for compound 1, IC50=1.0 
nM for compound 2). Zymography analysis demonstrated that each compound was also 
effective, at nanomolar concentration, to inhibit the activity of cell derived MMP-2 
tested on the natural substrate, gelatin. Moreover, the results demonstrated that IC50 
nanomolar concentrations of compounds 1 and 2 can affect cell parameters, such as 
invasiveness, without affecting viability and proliferation. The low active concentration 
of compounds should spare the inhibition of both protective MMPs (anti-cancer) and 
those MMPs involved in other cell processes, probably resulting in reduced toxicity 
compared to broad-spectrum MMP inhibitors, such as CGS_27023A. Indeed, in order to 
obtain a more specific action with fewer side effects, the recent strategy is to use MMP 
inhibitors at very low-dosage. Compound 1 has been employed at a very low dose (4.5 
pmol) in mouse experiments to investigate the role of MMP-2 and MMP-9 in 
neuropathic pain development (Kawasaki Y et al., 2008). In a previous study, compound 
1 has been demonstrated to affect the invasive activity of the fibrosarcoma cell line, 
HT1080 (Rossello A et al., 2004). Treatment of U87MG glioma cells with compounds 1 
or 2 for 24 h evidenced their ability to inhibit cell invasiveness without affecting 
viability, demonstrating their activity on different types of cancer. Compounds 1 and 2 
were used at nanomolar concentrations, corresponding to their IC50 values for MMP-2, 
even though we cannot exclude that the observed inhibitory effects on invasiveness may 
be partly mediated by inhibition of MMP-9 and MMP-12. Indeed, MMP-9 and MMP-
12 have been demonstrated to play a cooperative tumour-promoting effect, together 
with MMP-2, in GBM (Forsyth PA et al., 1999, Wang M et al., 2003). Thus, the 
inhibition of all these proteases could contribute to the arrest of cell invasiveness. 
On the other hand, we found that the tested compounds inhibited MMP-2 
expression at both the mRNA and protein levels. Our results are consistent with those of 
other researchers who have found a reduction of MMP-2 expression levels following 
treatment of tumoral cells with other MMP inhibitors (Lee SK et al., 2007). Further 
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studies are required to clarify the molecular mechanisms underlying the MMP-2 
expression decrease in our experimental conditions. 
Appropriate combinations of MMP inhibitors with other chemotherapeutic 
agents may prove to be a very effective anti-cancer strategy. The combination of MT, a 
broad spectrum MMP inhibitor, with cytotoxic compounds, such as TMZ, has shown 
interesting results deserving further studies to minimize the side effects associated with 
the use of MMP inhibitors (Levin VA et al., 2006). 
In line with this strategy, the U87MG cell parameters were investigated after 
treatments with TMZ alone and in combination with compounds 1 or 2. The treatment 
of U87MG cells with TMZ markedly reduced the number of viable cells. These data are 
in line with previous studies reporting that TMZ induces G2-M arrest in human U87MG 
glioma cells, and this is the most prominent effect of TMZ in gliomas (Hirose Y et al., 
2001). Compounds 1 or 2 did not affect the anti-proliferative activity of TMZ. Indeed, 
these co-treatments evidenced a significant reduction in the number of proliferating 
cells compared to that obtained in the control cells. On the other hand, the potent 
inhibitory effect of compounds 1 and 2 on invasiveness of glioblastoma cells was also 
observed during co-treatments with TMZ, suggesting that TMZ did not inhibit the anti-
invasive property of these compounds. 
In conclusion, taken together, these data suggest that this combination of drugs 
may have good therapeutic potential for the treatment of brain tumours. The ability of 
glioma cells to proliferate quickly and to infiltrate the surrounding brain tissues, 
escaping current therapeutic modalities, could be minimized using the combined 
treatment. These co-treatments could block the growth of the tumour by means of an 
alkylating agent, such as TMZ, and could stop the invasiveness through MMP-2 
inhibitors. Moreover, the ability of MMP inhibitors 1 and 2 to act at nanomolar 
concentrations paves the way in developing efficacious clinical glioblastoma combined 
therapies without the side effects typically associated with broad spectrum MMP 
inhibitors. 
 
 
 
 
 
71 
4.2 Biological Evaluation in U87MG Glioma Cells of 
(Ethynylthiophene)Sulfonamido-Based Hydroxamates as Matrix 
Metalloproteinase Inhibitors 
 
 
Material and Methods 
 
U87MG cell culture 
U87MG cells: see chapter 3 
 
MMP inhibition assays 
Recombinant human MMP-14 catalytic domain was a kind gift of Prof. Gillian 
Murphy (Department of Oncology, University of Cambridge, UK). Pro-MMP-1, pro-
MMP-2, pro-MMP-3, pro-MMP-8, and pro-MMP-9 were purchased from Calbiochem.  
Proenzymes were activated immediately prior to use with p-
aminophenylmercuric acetate (APMA 2 mM for 1 h at 37 °C for MMP-2 and MMP-8, 
APMA 2 mM for 2 h at 37 °C for MMP-1, 1 mM for 1 h at 37 °C for MMP-9). Pro-
MMP-3 was activated with trypsin 5 µg/mL for 30 min at 37 °C followed by soybean 
trypsin inhibitor 62 µg/mL. For assay measurements, the inhibitor stock solutions (10 
mM in DMSO) were further diluted, at 7 different concentrations for each MMP in the 
fluorometric assay buffer (FAB: Tris 50 mM, pH = 7.5, NaCl 150 mM, CaCl2 10 mM, 
Brij 35 0.05% and DMSO 1%). Activated enzyme (final concentration 0.5 nM for 
MMP-2, 1.3 nM for MMP-9, 1.5 nM for MMP-8, 5.0 nM for MMP-3, 1.0 nM for 
MMP-14cd, 2.0 nM for MMP-1) and inhibitor solutions were incubated in the assay 
buffer for 2 h at 25 °C. After the addition of the fluorogenic substrate Mca-Arg-Pro-Lys-
Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 (Sigma) for MMP-3 and Mca-Lys-Pro-Leu-
Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 (Bachem) for all the other enzymes in DMSO (final 
concentration 2 μM), the hydrolysis was monitored every 15 s for 15 min, recording the 
increase in fluorescence (λex = 325 nm, λem = 395 nm) with a Molecular Devices 
SpectraMax Gemini XS plate reader. The assays were performed in duplicate in a total 
volume of 200 μL per well in 96-well microtiter plates (Corning black, NBS). The 
MMP inhibition activity was expressed in relative fluorescent units (RFU). Percent of 
inhibition was calculated from control reactions without the inhibitor. IC50 was 
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determined using the formula: Vi/Vo = 1/(1 + [I]/ IC50), where Vi is the initial velocity of 
substrate cleavage in the presence of the inhibitor at concentration [I] and Vo is the 
initial velocity in the absence of the inhibitor. Results were analyzed using SoftMax Pro 
software and GraFit software. 
 
Cell treatment  
U87MG cells were seeded at 30,000 cells/cm
2
 in serum-free medium and 
incubated in the absence (control) or presence of the MMP inhibitors for 24 h. The 
MMP inhibitors were tested at a single concentration (5 nM). Compound 5a was tested 
also at 1, 5, 25, 125 nM concentrations to verify the dose-dependency of cell 
invasiveness inhibition. The vehicle (DMSO) in which the compounds were dissolved 
never exceeded 1% of the final volume of culture medium. 
 
Trypan Blue exclusion assay 
Cell viability in serum-free medium after drug treatments was measured by the 
Trypan Blue exclusion assay, as reported in the precedent section.  
 
Matrigel invasion assay of U87MG glioma cells 
This method was employed to evaluate cell invasiveness after treatments with 
MMP inhibitors, as reported in the precedent section 
 
Statistical analyses 
The nonlinear multipurpose curve-fitting program Graph-Pad Prism was used 
for data analysis and graphic presentations. All data are presented as the mean ± SEM 
derived from at least three independent experiments done in duplicate. p<0.0001 was 
considered statistically significant. 
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Results and discussion 
 
MMPs inhibition  
The newly synthesized hydroxamates 4-7 were tested in vitro for their ability to 
inhibit human recombinant MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, and MMP-14 
by a fluorometric assay, which used a fluorogenic peptide as the substrate. The broad 
spectrum inhibitor 3 was taken as reference compound (Table 2).  
 
Table 2. In vitroa activity (IC50 nM values) of 4-butylethynylthiophene derivatives 4, 5a-d, 6, 
7 and the reference compound 3. 
 
 
a
Enzymatic data are mean values for three independent experiments performed in duplicate. 
SD were generally within ±10%.  
 
As can be seen from data in Table 2, the introduction of various (R) aryl-alkyl 
chains in position α of the hydroxamate did not substantially affect activity toward 
MMP-2 with respect to the un-substituted derivative 4. In fact, all α-substituted 
compounds displayed nanomolar inhibitory activity for MMP-2 (IC50 values between 
1.3 and 17 nM) comparable to compound 4 activity (IC50 = 1.5 nM). As expected, these 
data confirmed that the activity for MMP-2 was principally determined by the P1’ 
group, a 4-butylphenylethynylthiophene substituent, which is the same for all 
compounds. On the contrary, the selectivity profile was greatly affected by the presence 
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of the α-chain (P1 group) and by its structure. The cyclic derivatives 6 and 7, bearing a 
thiazolidine and a tetrahydroisoquinoline ring respectively, were poorly selective over 
the anti-target MMPs. In particular, the tetrahydroisoquinoline derivative 7 was the least 
selective of the series, having nanomolar activity toward all tested enzymes, except 
MMP-1. Among the non-cyclic inhibitors, the benzyloxy benzyl derivative 5a was the 
most active on both MMP-2 and MMP-9 (IC50 = 2.3 nM and 63 nM, respectively), 
showing the highest selectivity over MMP-1, -3, -8 and -14. This compound exhibited a 
2000-fold selectivity for MMP-2 over MMP-1, a 1000-fold selectivity over MMP-14, a 
200-fold selectivity over MMP-8 and a 80-fold selectivity over MMP-3. These very 
good selectivity data are probably due to the presence of a more bulky α-chain 
compared to the other derivatives. The benzothienyl derivative 5d resulted the weakest 
inhibitor of MMPs, on all tested enzymes.  
 
Matrigel invasion assay and viability assay on human U87MG 
glioma cells.  
Firstly, the ability of the newly synthesized gelatinases inhibitors 4-7 and the 
reference compound 3 to inhibit invasion through Matrigel was evaluated using U87MG 
cells. In addition, potential cytotoxicity of these compounds was determined on parallel 
cultures using the trypan blue exclusion method. The data, shown in Table 3, indicate 
that drug treatments only slightly reduced the cell survival of glioma cells (p>0.05) after 
a 24 h incubation of the cells at a 5 nM concentration of the inhibitors. Furthermore, 
MMPI-treated U87MG cells with a 5 nM inhibitor dose showed a marked reduction 
(p<0.0001) in invasion through Matrigel after 24 h, as shown in Table 3. Invasion data 
were normalized by subtracting the percentage of dead cells at the end of the assay, 
which did not exceed an average of ~15% among the different compounds. 
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Table 3. In vitro cellular activity in U87MG cell line of synthesized compounds 4-7 and the 
reference compound 3. 
 
 
a
 Percent inhibition observed at 5 nM concentration of the tested compounds, normalized to 
cell death. Invasion data were normalized by subtracting the percentage of dead cells at the end of the 
assay, which did not exceed an average of ~15% among the different compounds. 
 
Taken together, these results identify a new series of MMPIs with potent anti-
invasive activity at nanomolar concentrations without cytotoxicity in cultured glioma 
cells. Furthermore, all compounds, except the cyclic derivative 6, were more active than 
the broad spectrum inhibitor 3. In particular, as shown in Figure 11A, compounds 5c 
and 5a displayed the highest inhibitory activity of cell invasiveness (48 and 43% at 5 
nM, respectively). As shown in Figure 11B, a dose-dependent cell invasiveness 
inhibition was observed following treatment with 1, 5, 25, 125 nM concentrations of 
compound 5a (IC50 = 12 nM). 
From these data, it appears evident that probably MMP-2 is not the only 
enzyme responsible for the invasion process in glioma cells. In fact, according to 
inhibition data on isolated enzymes (Table 2), all these compounds have similar activity 
on MMP-2 but they show different ability to inhibit invasion (from 16 to 48% 
inhibition). However, selectivity for MMP-2 and MMP-9 seems to be fundamental to 
achieve activity on glioma cells, because compound 5a was the one with the best 
selectivity profile on MMP-2 and MMP-9. 
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11B. 
Figure 11. Effect of MMPIs on U87MG cell invasiveness. (A) Treatment of cells with 
compounds 4-7 and the reference compound 3 (5 nM) for 24 h reduced the invasiveness of glioma cells. 
(B) Dose-dependent cell invasiveness inhibition following treatment with compound 5a for 24 h. The IC50 
value represents the compound concentration producing a 50% decrease in tumor cells invasiveness. The 
results are expressed as the mean value of the inhibition percentage of invasive cells observed after 
treatment compared to untreated control cells.*** = statistically significant result (p<0.0001). 
 
The migration of cells treated with compounds 5a, 5c or the reference 
compound 3 is shown in Figure 12. 
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Figure 12. Cell invasion was analysed using the Matrigel basement membrane transwell 
system as described in Experimental Section. Images in the figure panels show cells that migrated to the 
lower surface of the transwell membrane. The magnification was 200x. The migration of untreated cells is 
shown in the panel marked DMSO. The migration of cells treated with compounds 5a, 5c or the reference 
compound 3 is shown in other panels. 
 
Conclusion 
 
In this chapter section, a small series of new 4-
butylphenyl(ethynylthiophene)sulfonamido-based hydroxamate inhibitors for MMP-2, 
selective over MMP-1 and MMP-14, was tested for their ability to inhibit glioma cell 
invasion in vitro. Among these compounds, a very promising derivative was identified 
(5a) with nanomolar activity for MMP-2 and MMP-9 and good selectivity over the anti-
target MMP-8 and MMP-3, by fluorometric assay on isolated enzymes. To assess the 
new hydroxamates activity in cells, Matrigel invasion assay and viability assay on 
human U87MG glioma cells were performed. No toxicity was detected for these 
compounds at the nM concentration used, and 5a was found to inhibit by 43% glioma 
invasiveness at 5 nM (IC50 = 12 nM). Finally, this compound has been shown to 
possess a nanomolar inhibitory activity against MMP-25, a recently discovered target 
involved in glioma progression (data not shown, see Nuti E et al., 2011). After the 
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disappointing clinical results of broad spectrum MMP inhibitors in cancer therapy of the 
last years, this preliminary study, together with the results reported in the previous 
section of this chapter (section 4.1), has the aim to reopen the search for more selective 
MMPIs with anti-invasive activity to be used also in combination with cytotoxic 
compounds, as TMZ (Gabelloni P et al, 2010). The use of more specific and efficacious 
inhibitors should allow to reduce the doses necessary to have therapeutic efficacy 
without the side effects typically associated with broad spectrum MMP inhibitors. 
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Chapter 5: Glioblastoma multiforme II 
 
p53 reactivation by the new small-molecule ISA27 MDM2 
inhibitor is highly effective in inducing apoptosis of U87MG human 
glioblastoma multiforme cells. 
 
The dysregulation of intracellular mechanisms mediated by p53, the main 
cellular gatekeeper, plays a crucial role in the high resistance of GBMs to DNA-
damaging therapy (Ohgaki H and Kleihues P, 2009). 
It is indeed a transcription factor that acts as a tumor suppressor and mediator 
of cell cycle and has been called "the guardian of the genome", referring to his role in 
the preservation of stability by preventing mutations. In normal circumstances, 
following DNA damage, the activation of the p53 pathway results in cell cycle arrest to 
allow DNA repair, and if the DNA lesion is too extensive, p53 induces apoptotic cell 
death (Vousden KH and Lu X, 2002). 
In GBM, p53 function is frequently impaired, and cells became resistant to 
apoptosis induced by genotoxic damage. In a small percentage of cases, the gene 
encoding p53 is mutated, rendering the p53 protein inactive (Ohgaki H and Kleihues P, 
2009, Vousden KH and Lu X, 2002, Cerami E et al., 2010). In the majority of cases, p53 
retains its wild-type status, but its function is effectively inhibited by the Murin-Double-
Minute-2 (MDM2) oncoprotein, the primary cellular inhibitor of p53 (Cerami E et al., 
2010, He J et al., 1994). 
The MDM2 protein tightly controls p53 activity through an autoregulatory 
feedback loop; p53 activates MDM2 expression, which in turn represses p53 by three 
mechanisms. First, the MDM2 protein binds p53 at its transactivation domain and 
blocks its ability to activate transcription. Second, MDM2 exports p53 out of the 
nucleus. Third, MDM2 promotes the proteosome-mediated degradation of p53 through 
its E3 ubiquitin ligase activity (Freedman DA et al., 1999, Juven-Gershon T and Oren 
M, 1999, Wu X et al., 1993). In GBMs, genetic alterations that cause MDM2 
overexpression and excessive nuclear accumulation have been reported (Ohgaki H and 
Kleihues P, 2009, Cerami E et al., 2010, Halatsch ME et al., 2006) and documented in 
approximately 15% of GBMs. 
The loss of the locus containing the gene for PTEN (a protein that counteracts 
excessive MDM2 nuclear accumulation) has been found in up to 80% of GBMs. 
80 
All of these data suggest that the restoration of p53 function is an appealing 
approach to treating GBMs. Several distinct approaches have been pursued to restore 
p53 function as a new cancer therapeutic strategy (Chène P, 2003, L.T. Vassilev LT et 
al., 2004, Wiman KG, 2006). 
Three recent studies, using unique genetic models, have demonstrated that p53 
restoration universally leads to a rapid and robust regression of established sarcomas, 
lymphomas and liver tumors (Xue W et al., 2007, Ventura A et al., 2007). 
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Experimental section 
 
 
p53-MDM2 inhibitors 
 
One attractive pharmacological approach to p53 reactivation is to use a small 
molecule to block the MDM2-p53 interaction. The discovery of the Nutlins provided 
the important proof of concept for this approach, as they have been shown to bind to 
MDM2, block the MDM2-p53 interaction, activate p53 and induce apoptotic cell death 
in several tumor models. Interestingly, these drugs have been reported to induce cancer 
cell apoptosis even without the concomitant application of DNA-damaging agents. 
Nutlin-3 has recently entered phase I clinical trials with patients suffering from 
advanced solid cancers or hematologic malignancies. 
To the best of our knowledge, little is known about the efficacy of MDM2 
inhibitors in human GBMs, although a study of the effect of Nutlin-3 on GBM cells was 
published while this thesis was written. We investigated whether a novel small-molecule 
MDM2 inhibitor, named ISA27, affected the growth of the U87MG human GBM cell 
line and compared its efficacy with that of Nutlin-3. We chose U87MG cells because 
they express wild-type p53 and are PTEN-null (Kondo S et al., 1995). 
 We showed that ISA27 activated the p53 pathway in U87MG cells and elicited 
a dose- and time dependent inhibition of cell growth by the induction of permanent cell 
cycle arrest and apoptosis. Compared to Nutlin-3, ISA27 was effective at a lower dose 
and caused a faster antiproliferative response. 
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Materials and Methods 
 
U87MG cell line culture and preparation of circulating cell 
samples 
- U87MG cells: see chapter 3. 
- Blood samples were drawn into test tubes containing Li-Heparin and then 
processed for mononuclear cell preparation according to the method of Boyum (Boyum 
A, 1969). The final cell pellet was re-suspended in complete RPMI 1690 media 
supplemented with 15% FBS, 2 mM L-glutamine, 100 units/ml penicillin and 100 
mg/ml streptomycin. To evaluate cell populations, random cell samples (n=7) were 
employed for flow cytometric analysis. 
 
Cell treatment with MDM2 inhibitors 
For U87MG cell treatment, the cells were seeded at 5,000 cells/cm2. After 24 
h, the culture medium was replaced with fresh medium with ISA27 (Gomez-Monterrey 
I et al., 2010) or Nutlin-3 for the indicated incubation times. DMSO was added to 
control cells (<1% v/v). For short-term treatment (24 h), U87MG cells were incubated 
with increasing concentrations of the MDM2 inhibitors (from 5 nM to 15 µM). For long 
term treatment (up to 5 days), U87MG cells and lymphomonocytes were incubated with 
2.5 µM ISA27 or 10 µM Nutlin-3. 
 
Cell survival/growth analysis 
The effects of MDM2 inhibitor treatment on U87MG cell survival/growth were 
estimated by MTS conversion (Chelli B et al., 2004) and Trypan blue exclusion assays ( 
Ruan S et al., 1999). The MTS assay was used to establish the MDM2 inhibitor 
concentration that inhibited 50% (IC50 value) of the cell survival/growth after 24 h of 
treatment and was performed according to the manufacturer’s instructions. Sigmoidal 
dose-response curves were generated using Graph Pad Prism 4 software (GraphPad 
Software Inc., San Diego, CA), from which the IC50 values were derived. Trypan blue 
dye exclusion was used to examine the long-term effects of MDM2 inhibitor treatment 
on U87MG cell and lymphomonocyte viability at the indicated times. 
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Analysis of the complex p53-MDM2 levels 
The complex p53-MDM2 levels in U87MG cells were determined using the 
Assay Design® p53-MDM2 Immunoset. Cell lysates (3.2 µg of protein) were added to 
multi-well plates that were previously coated with p53 antibody and incubated for 1 h. 
After 4 washings, MDM2 antibody was added to each well and then incubated with a 
colorimetric enzyme substrate and analyzed at 450 nm. The p53-MDM2 complex 
amount was determined according to a standard curve. The percentage of the complex 
in samples from MDM2 inhibitor treated-cells was calculated with respect to untreated 
cells, at which 100% was attributed. 
 
Relative mRNA quantification of target p53 genes 
The relative mRNA quantification of target p53 genes in untreated and MDM2 
inhibitortreated cells was performed by real-time polymerase chain reaction (real-time 
PCR) as described in the chapter 4. The primer sequences used were: 
 
MDM2 forward, 5’-TCTAGGAGATTTGTTTGGCGT-3’; 
MDM2 reverse, 5’-TCACAGATGTACCTGAGTCC-3; 
p21 forward, 5’-AAGACCATGTGGACCTGTCACTGT-3’; 
p21 reverse, 5’-GAAGATCAGCCGGCGTTTG-3’; 
PUMA forward, 5’-TCCTCAGCCCTCGCTCTCGC-3’; 
PUMA reverse, 5’-CCGATGCTGAGTCCATCAGG-3’; 
ß-actin forward, 5’-GCACTCTTCCAGCCTTCCTTCC-3’; 
ß-actin reverse, 5’-CGTGTGGATCGGCGGCTC-3’. 
 
Cell cycle analysis 
Cell cycle analysis was performed by flow cytometric analysis (FACScalibur 
flow cytometer, Becton Dickinson, USA) (Chelli B et al., 2004, Chelli B et al., 2005). 
The percentage of PI-stained untreated and MDM2 inhibitor-treated cells was 
estimated in each cell cycle phase using the ModFit LT software program. 
 
Cellular senescence assays 
The senescence marker SA-β-Gal was detected as previously described (Dimri 
GP et al., 1995), and cells were then washed in PBS (1X) and photographed at 100X 
magnification. Images of random light microscopic fields were captured (5 fields per 
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well), and cells were counted using ImageJ (ImageJ Software, version 1.41o; USA). The 
average cell size was assessed using the Scepter 2.0 handheld automated cell counter 
(Millipore, Billerica, MA, USA). 
 
Analysis of apoptotic parameters 
Mitochondrial membrane potential (ΔΨm). Changes in..m were assessed using 
the fluorescent dye JC-1 as previously described (Chelli B et al., 2004, Chelli B et al., 
2005), and fluorescence was analyzed by FACS. As a positive control, a cell pellet was 
incubated with the uncoupling agent CCCP (50 µM). 
Cytosolic Cytochrome c release from mitochondria. The cytosol fraction from 
untreated and MDM2 inhibitor-treated cells was obtained using the mitochondrial 
fractionation Active Motif ® Kit according to the manufacturer’s instructions. The 
cytosolic protein content was determined as previously described (Dimri GP et al., 
1995), and the cytochrome c content was determined using the Platinum Human 
Cytochrome c ELISA. The minimum detectable dose of cytochrome c was 0.05 ng/mL. 
DNA fragmentation analysis. DNA fragmentation was estimated by evaluating 
the DNA PI staining using FACS. The percentage of apoptotic cells was estimated as 
previously described (Chelli B et al., 2004, Chelli B et al., 2005). The percentage of 
cells in the sub-G0 fraction was determined using the ModFit LT software program. 
 
Statistical analyses 
The nonlinear multipurpose curve-fitting program Graph-Pad Prism was used 
for data analysis and graphic presentations. All data are presented as the mean ± SEM. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) with 
Bonferroni’s corrected t-test for post-hoc pair-wise comparisons. P < 0.05 was 
considered statistically significant. 
 
 
 
 
 
 
 
 
85 
Results 
 
Lower dose of ISA27 restores p53 function and inhibits U87MG 
cell growth/survival than that of Nutlin-3 
GBM cells were treated with the small molecule ISA27 (see Figure 1 for 
chemical structure) because it efficiently dissociated the reconstituted human MDM2-
p53 complex (Gomez-Monterrey I et al., 2010). To evaluate ISA27 efficacy, parallel 
experiments were performed using Nutlin-3, the standard MDM2 inhibitor (Vassilev LT 
et al., 2004). The GBM cell model was the U87MG human GBM cell line because it 
expresses wild-type p53 and overexpresses MDM2 (Kond S et al., 1995, Zhao P et al., 
1998). 
To examine the effects of ISA27 on U87MG cell growth/survival and compare 
its efficacy with that of the standard Nutlin-3, the concentration at which each small-
molecule inhibitor inhibited 50% of cell growth (IC50 value) after 24 h of treatment 
was estimated. Both small molecules had a dose-dependent inhibitory effect on cell 
growth/survival. The IC50 values were 2.5±0.4 µM for ISA27 and 10±2.1 µM for 
Nutlin-3, indicating that ISA27 is a more potent cell growth/survival inhibitor than 
Nutlin-3. These IC50 inhibitor concentrations were then used in the following 
experiments. 
Next, we evaluated whether ISA27 was able to disrupt the intracellular 
MDM2-p53 interaction with the same efficiency as reported in a cell-free system 
(Gomez-Monterrey I et al., 2010). The ISA27-treated cells showed a statistically 
significant reduction in MDM2-p53 complex formation compared to control cells 
(t=5.48, p<0.01) (Figure 1A). Comparable results were obtained with Nutlin-3 (t= 6.16, 
p<0.01) (Figure 1A). 
MDM2 inhibition should stabilize p53 and induce the expression of p53 target 
genes. Thus, we examined the effect of ISA27 on the mRNA levels of the two p53 
target genes MDM2 and p21. Short-term ISA27 treatment led to a statistically 
significant increase in MDM2 and p21 mRNA. Specifically, ISA27 caused a 4.3- and 
4.5-fold induction of MDM2 and p21 mRNA, respectively (for MDM2: t=3.87, p<0.01; 
for p21: t=8.26, p<0.001) (Figure 1B). These results suggest that the low MDM2-p53 
complex formation in ISA27-treated U87MG cells leads to an elevation in the MDM2 
and p21 mRNA levels in a manner that is consistent with activation of the p53 pathway. 
The standard Nutlin-3 caused a 2.3- and 4.3-fold induction of MDM2 and p21 mRNA, 
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respectively (for MDM2: t=3.43, p<0.05; for p21: t=7.79, p<0.001) (Figure 1B). One of 
the main cellular consequences of p53 activation in proliferating cells is cell cycle arrest 
at the G1/G2 phases, and the cyclin-dependent kinase inhibitor p21 plays a major role in 
this arrest. Cell cycle analysis by cytofluorimetric DNA content analysis revealed an 
increase in the G1 fraction and a nearly complete depletion of S-phase cells after ISA27 
or Nutlin-3 short-term treatment (Figure 1C). 
 
Figure 1. ISA27 restores p53 function in U87MG cells. 1A) ISA27 reduces MDM2-p53 
complex formation: A significant reduction in MDM2-p53 complex formation was shown following 
short-term treatment with ISA27 or Nutlin-3. 1B) ISA27 induces p53 target gene expression: Real-time 
PCR analyses showed a statistically significant increase in MDM2 and p21 mRNA levels following short-
term ISA27 or Nutlin-3 treatment. 1C) ISA27 induces cell cycle arrest: cell cycle analysis revealed a 
statistically significant increase in the G1 fraction and a nearly complete depletion of the S-phase in short-
term-treated cells.  
 
Long-term ISA27 treatment leads to the complete inhibition of U87MG 
GBM cell growth but not that of normal lymphomonocytes 
U87MG cells were exposed to ISA27 for 5 days and then viable and dead cells 
were counted at indicated time points. A substantial decrease in cell survival was 
observed after one day of treatment and progressed at each subsequent time point, until 
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almost all viable cells were depleted after 5 days (Figure 2A). When the time-course 
curves of ISA27 and Nutlin-3 were compared, the data showed that ISA27 was able to 
reduce U87MG cell viability faster than Nutlin-3 (Figure 2A). We also examined the 
effect of ISA27 on the viability of normal human lymphomonocytes. Flow cytometry 
was performed to evaluate cell populations isolated from blood samples of healthy 
individuals. As shown in the scatter cytogram in Figure 2B, the two cell populations 
were clearly visible (G2= 74.0% lymphocytes; G3= 14.2% monocytes). As shown in 
Figure 2C, ISA27-treated lymphomonocytes were still viable by 48 h, suggesting that 
ISA27 is selective for cancer versus normal cells. Nutlin-3 showed a similar lack of 
cytotoxicity in this normal peripheral cell model (Figure 2C). 
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Figure 2. Long-term ISA27 treatment of U87MG cells and human lymphomonocytes. 
2A) Time-response curve of U87MG cell viability: The percentage of ISA27- (▼) or Nutlin-3- (■) 
treated viable cells was calculated with respect to untreated viable cells at the indicated incubation times. 
2B) Scatter cytogram analysis of cell populations from blood: Scatter cytogram analysis showing cell 
separation by size and granularity (G2=lymphocytes; G3=monocytes). One representative experiment is 
presented. 2C) Time-response of human lymphomonocyte viability following ISA27 treatment: No 
significant differences were observed between MDM2 inhibitor-treated and control viable or dead cells at 
each incubation time.  
 
Long-term ISA27 treatment leads to permanent cell cycle arrest and 
apoptosis in U87MG human GBM cells 
We first analyzed cell cycle profiling and p21 mRNA levels after long-term 
ISA27 treatment. ISA27 treatment of U87MG cells for 24 h effectively arrested cell-
cycle progression, depleted the S-phase population compartment (t=5.67, p<0.05) and 
increased the G0/G1-phase population (t=5.25, p<0.05), and treatment for 72 h depleted 
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the S-phase population and increased the G2-phase population (t=7.69, p<0.01) (Figure 
3A). A persistent induction of p21 mRNA was observed, suggesting that the major 
transcription target of activated p53 was involved in the cell cycle arrest (Figure 3B). 
Nutlin-3 arrested cell-cycle progression in U87MG cells 24 and 72 h after treatment, 
depleting the S-phase compartment and increasing the G0/G1-phase compartment 
(Figure 3A). 
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Figure 3. Long-term ISA27 treatment induces cell cycle arrest and persistent p21 
mRNA increase in U87MG cells. 3A) Flow cytometric cell cycle profiling: the figure shows the 
percentage of untreated and MDM2 inhibitor-treated U87MG cells in G1, S and G2/M phases. 3B) p21 
mRNA evaluation: ISA27 caused a statistically significant increase in p21 mRNA at 24, 48 and 72 h.  
 
To elucidate whether ISA27 induced permanent cell cycle arrest (cellular 
senescence) or reversible cell cycle arrest in U87MG cells, the ability of these cells to 
resume proliferation after ISA27 treatment was evaluated. The cells were incubated 
with ISA27 for 4 days, washed to remove the drug and then incubated for an additional 
4 days in fresh culture medium. After removal of the drug, U87MG cells barely 
resumed proliferation. We then evaluated whether ISA27 induced a morphological 
change in U87MG cells (i.e., large and flat cells), which is compatible with senescence, 
and whether the widely used senescence marker SA-β-Gal could be detected in ISA27- 
treated cells. The ISA27-treated cells acquired an enlarged and flat morphology as 
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revealed by measuring the mean cell diameter (12.36±1.56 .µm and 13.59±1.74 .µm for 
control and ISA27- treated cells, respectively). The onset of cellular senescence was 
rapid; indeed, a high number of U87MG cells were positive for SA-β-Gal after 1 day of 
treatment. Figure 4A shows representative images of SA-β-Gal detection in ISA27-
treated and control cells. As shown in Figure 4B, ISA27 significantly enhanced the 
number of SA-β-Gal-expressing cells after 24 h (t=4.04, p<0.01). Nutlin-3 caused an 
increase in the number of SA-β-Gal expressing cells also at both 24 (t=4.41, p<0.01) 
and 72 h (t=5.34, p<0.001). 
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Figure 4. ISA27 induces U87MG cell senescence.4A) Representative images of SA-β-Gal-
expressing cells: The panel shows the SA-β-Gal-expressing MDM2 inhibitor-treated and untreated cells 
at 72 h. 4B) Percentage of SA-β-Gal-expressing cells: The number of SA-β-Gal-expressing cells was 
expressed with respect to total cells in each sample (untreated cells, ISA27- and Nutlin-3-treated cells). 
The percentage of SA-β-Gal-expressing cells for MDM2 inhibitor-treated samples was then calculated 
with respect to untreated cells, at which 100% value was attributed.  
 
To investigate whether ISA27 induced apoptosis, the following parameters 
were evaluated: dissipation of mitochondrial potential (ΔΨm), cytosolic cythocrome c 
content, PUMA mRNA levels and DNA fragmentation. 
A decrease in ΔΨm was indicated by a reduction in orange JC-1 aggregate 
fluorescence (recorded by the FL 2 channel) accompanied by a concomitant increase in 
green JC-1 monomer fluorescence (recorded by the FL 1 channel). Representative 
examples of the cytometric analysis are given in Figure 5A. The majority of untreated 
cells (99%) showed high fluorescence emission in both channels and were found in the 
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upper right (UR) quadrant of the plot. The remaining (1%) of the untreated cells showed 
low fluorescence emission in FL2, therefore plotting in the lower right (LR) quadrant. 
For ISA27 treatment, an increase was seen in the percentage of the cells plotting in the 
LR quadrant, consistent with ΔΨm dissipation. In particular, significant changes in ΔΨm 
were observed after treatment at 24 and 48 h (8.5% and 31%, respectively; p<0.05), as 
shown in Figure 5B. 
 
 
Figure 5. ISA27 induces dissipation of the mitochondrial membrane potential. 5A) 
Representative dot-blots of untreated and MDM2 inhibitor-treated cells: After ISA27 treatment, 
mitochondrial depolarization is visible by a decrease and increase of fluorescence in the FL-2 and FL-1 
channels, respectively. After Nutlin-3 treatment, mitochondrial depolarization is not visible; CCCP is the 
positive control. 5B and C) Time-course analyses of ΔΨm dissipation: Histograms show the mean 
values of cell percentages either in the UR (polarized mitochondria) or LR (depolarized mitochondria) 
quadrant of the ΔΨm analysis plots derived from three independent experiments.  
 
Real time RT-PCR analysis showed that ISA27 led to a statistically significant 
PUMA mRNA level increase at 24 and 48 h compared to the control (Figure 6A). 
Figure 6B shows that ISA27-treated cells exibited a 25% increase in 
cytochrome c in the cytosolic fraction compared to the control. DNA-specific PI 
staining showed that treatment with ISA27 caused a significant increase in the 
percentage of cells with hypodiploid DNA content, a clear sign of apoptosis, as shown 
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in the frequency histograms from a representative flow cytometric experiment (Figure 
6C). In particular, the quantity of apoptotic cells (sub-G0 cells) observed after exposure 
of U87MG cells to ISA27 for 72 h increased to 17.7±1.27% (p<0.001), while that of the 
control was 0.43±0.05%. Nutlin-3 did not give statistically significant results after the 
indicated incubation times for these apoptotic parameters (Figure 6B and 6C), with the 
exception of increased PUMA mRNA levels after treatment for 72 h (Figure 6A). 
 
 
 
Figure 6. ISA27 induces an increase in PUMA mRNA levels, mitochondrial cytochrome 
c release, and DNA fragmentation. 6A) PUMA mRNA relative quantification: ISA27 induced a 
statistically significant increase in PUMA mRNA levels at 24 and 48 h. Nutlin-3 caused a statistically 
significant increase at 72 h. 6B) Cytosolic cytochrome c content evaluation: ISA27-treated cells showed 
a 25% increase in cytochrome c in the cytosolic fraction. Nutlin-3-treated cells did not give statistically 
significant results. 6C) DNA content evaluation: Frequency histograms from a representative experiment 
are shown. ISA27-treated cells showed a significant increase in the percentage of nuclei with hypodiploid 
DNA content at 72 h compared with control cells. In contrast, Nutlin-3 did not induce significant nuclear 
DNA fragmentation. 
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Discussion 
 
The direct and specific activation of the p53 pathway without inducing 
collateral DNA damage offers a tantalizing answer to the shortcomings of current 
therapeutic regimens and seems to be a reasonable approach for GBM therapy in view 
of the infrequent occurrence of p53 gene mutations (Cerami E et al., 2010, He J et al., 
1994). 
The cumulative evidence of aberrantly increased activity of the primary p53 
inhibitor MDM2 in GBMs (Ohgaki H et al., 2009, Cerami E et al., 2010, Halatsch ME 
et al., 2006) incited us to examine the effects of targeted inhibition of the MDM2-p53 
interaction by the spiro-oxindole analog ISA27, a recently introduced MDM2 small 
molecule inhibitor (Gomez-Monterrey I et al., 2010). Little is known about the effects 
of MDM2 inhibitors on the in vitro growth of GBM cells. Recently, Nutlin-3, the first 
potent MDM2 small-molecule inhibitor (Vasilev LT et al., 2004), was reported to be 
effective at inhibiting in vitro GBM cell growth (Villalonga-Planells R et al., 2011), 
suggesting the validity of this experimental approach for the treatment of GBMs. 
In this study, we investigated whether ISA27 affected the growth of GBM cells 
and explored the intracellular effects activated following ISA27 treatment. Moreover, 
we compared the results with those obtained using Nutlin-3 to evaluate the efficacy of 
ISA27. The U87MG cell line was chosen as a cell culture model of human GBM 
because it maintains wild-type p53 (Kondo S et al., 1995, Zaho P et al., 1998). In this 
cell line, the primary mechanism of p53 inactivation is through high nuclear MDM2 
levels caused by a lack of PTEN, a tumor suppressor protein that counteracts MDM2 
translocation into the nucleus under normal circumstances (Mayo LD et al., 2002). The 
lack of PTEN makes this cell line a suitable representative model of GBM, as the loss of 
the locus containing the gene for PTEN has been found in up to 80% of GBMs (Ohgaki 
H et al., 2009, Cerami E et al., 2010, Halatsch ME et al., 2006). In addition, U87MG 
cells exhibit an efficient DNA repair system that has been associated with peculiar 
aberrant cell proliferation and resistance to conventional DNA-damaging therapy (Pegg 
AE, 1990, Dhandapani, KM et al., 2007). 
This is the first report to demonstrate that ISA27 is a potent inhibitor of 
U87MG cell growth. Previous studies have shown that ISA27 activates p53, resulting in 
growth inhibition in HEK-293 transformed human embryonic kidney, M14 human 
melanoma and U937 human monocyte lymphoma cell lines (Gomez-Monterrey I et al., 
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2010). Our results demonstrated that ISA27 blocks the cell cycle and triggers an 
apoptotic death program in U87MG cells, which are similar to the responses obtained 
with human M14 melanoma cells. 
We observed a dose-dependent antiproliferative effect in U87MG cells 
following short-term treatments (24 h) with increasing ISA27 concentrations. Moreover, 
ISA27 inhibited U87MG cell growth at a lower dose than Nutlin-3. The specificity of 
the antiproliferative effects was demonstrated by the reduction of MDM2-p53 complex 
formation and the restoration of p53 function in U87MG cells after ISA27 treatment. 
The reactivation of p53 was suggested by the induction of the transcriptional activation 
of the primary target p53 genes MDM2 and CDKN1A. The CDKN1A gene encodes the 
cyclin-dependent kinase inhibitor p21, an essential mediator of p53-induced cell cycle 
arrest. Exponential U87MG growth was significantly inhibiting following long-term 
ISA27 treatment. The number of viable cells was substantially reduced after 1 day of 
ISA27 treatment, and this reduction reached almost total growth inhibition after 5 days. 
Kinetic analyses of the ISA27-induced intracellular effects showed that the decrease in 
viable cells was mainly due to a G1 cell cycle block and cellular senescence during the 
initial phase of ISA27 treatment. However, apoptotic parameters, such as the dissipation 
of mitochondrial membrane potential, began to appear. Prolonged ISA27 exposure time 
caused a further decline in viable cells, a G2 cell cycle block and apoptosis of the 
remaining cells. By analyzing U87MG gene expression and apoptotic parameters in 
response to ISA27, we identified the upregulation of the PUMA gene, which is involved 
in mediating the apoptotic response of p53, mitochondrial potential dissipation, 
cytochrome c release into the cytoplasm and DNA fragmentation, all features consistent 
with apoptotic cell death. 
It is important to note that even long-term treatment of Nutlin-3 effectively 
inhibited U87MG cell growth. The primary cellular response to Nutlin-3 was the 
permanent cell cycle arrest that continued until the end of treatment. Only in the final 
stage of treatment did apoptosis signs begin to appear, as indicated by high levels of 
PUMA mRNA. This finding is consistent with literature data that reported U87MG 
apoptosis after Nutlin-3 treatment for 96 h (Villalonga-Planells R et al., 2011). As 
described above, ISA27 triggered a permanent cell cycle arrest, although this response 
induced early apoptosis. The comparison between long-term ISA27 and Nutlin-3 
treatment indicated that ISA27 stimulates a faster antiproliferative response than Nutlin-
3, inducing a more effective reduction in the number of viable cells. This feature of 
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ISA27 may be beneficial in the treatment of human GBM, considering that this cancer 
is characterized by rapid cell growth. Cellular responses with different kinetics have 
been recently shown for ISA27 and another small molecule, 10d, in the M14 human 
melanoma cell line (Gomez-Monterrey I et al., 2010). Treatment with ISA27 for 24 h 
induced both cell cycle arrest and apoptosis, while caused cell cycle arrest only. 
It is not clear how Nutlin-3 and ISA27 stimulate cellular responses with 
different kinetics in U87MG cells. ISA27 may induce a faster dissociation of p53 from 
MDM2 than Nutlin-3, and this more rapid reactivation of p53 function could be 
favorable for apoptosis induction. 
Of significant importance is that the Nutlin-3 and ISA27 are non-toxic in 
normal cells. Specifically, they did not reduce the viability of a normal human cell 
model (lymphomonocytes). This result is consistent with those previously obtained by 
other authors using a number of normal cell models and suggests a selective toxic effect 
of MDM2 inhibitors on cancer cells. It has been demonstrated that Nutlin-3 is not toxic 
to peripheral blood mononuclear cells, bone marrow-derived hematopoietic progenitors 
and bone marrow stromal epithelium cells (Secchiero P et al., 2006, Stühmer T et al., 
2005, Kojima K et al., 2005). In in vivo studies, Nutlin-3 and other MDM2 inhibitors 
showed antitumor activity in xenograft models of human cancers without causing 
visible signs of toxicity in the animals, as assessed by necroscopy analyses and body 
weight assessment (Vasilev LT et al., 2004, Tovar C et al., 2006, Shangary S et al., 
2008). 
The precise mechanism of cell death resistance in normal cells remains unclear. 
Cancer cells express a variety of oncogenes that provide a survival advantage to cancer 
cells but render them susceptible to oncogene intervention strategies. For example, 
cancer cells that are sensitive to MDM2 inhibitors show higher expression of the 
MDM2 oncoprotein than normal cells. Indeed, it was observed that MDM2 
overexpression in cancer cells is an indicator of their sensitivity to apoptosis induction 
by MDM2 inhibitors. Hence, MDM2 overexpression in cancer cells leads to a strong 
suppression of p53 activity and renders them highly susceptible to p53 reactivation by 
MDM2 inhibitors. It has also been proposed that different p53 levels in normal and 
cancer cells can explain the selective activity of the MDM2 inhibitors (Shangary S et 
al., 2008). It has been shown that although p53 is activated by a specific MDM2 
inhibitor in both normal colon fibroblast cells and HCT-116 colon cancer cells, the 
levels of p53 accumulation differ (Shangary S et al., 2008). Both basal and MDM2 
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inhibitor-induced p53 levels were appreciably lower in normal cells than in cancer cells. 
The authors of that study proposed that lower levels of p53 may favor cell cycle arrest, 
whereas higher levels of p53 lead to both cell cycle arrest and apoptosis induction. 
In conclusion, our data show that ISA27 disrupts the MDM2-p53 interaction 
and unchains the powerful antitumor capacities of p53 in U87MG GBM cells. If 
confirmed in vivo, the use of this MDM2 inhibitor could offer a novel therapy concept 
for the treatment of GBM patients by inducing tumor growth inhibition and regression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
